0001465470
false
FY
0001465470
2022-04-01
2023-03-31
0001465470
2022-09-30
0001465470
2023-06-21
0001465470
2023-03-31
0001465470
2022-03-31
0001465470
us-gaap:NonrelatedPartyMember
2023-03-31
0001465470
us-gaap:NonrelatedPartyMember
2022-03-31
0001465470
us-gaap:RelatedPartyMember
2023-03-31
0001465470
us-gaap:RelatedPartyMember
2022-03-31
0001465470
SHMP:SeriesERedeemableConvertiblePreferredStockMember
2023-03-31
0001465470
SHMP:SeriesERedeemableConvertiblePreferredStockMember
2022-03-31
0001465470
SHMP:SeriesFRedeemableConvertiblePreferredStockMember
2023-03-31
0001465470
SHMP:SeriesFRedeemableConvertiblePreferredStockMember
2022-03-31
0001465470
SHMP:SeriesEConvertiblePreferredStockMember
2023-03-31
0001465470
SHMP:SeriesEConvertiblePreferredStockMember
2022-03-31
0001465470
SHMP:SeriesAConvertiblePreferredStockMember
2023-03-31
0001465470
SHMP:SeriesAConvertiblePreferredStockMember
2022-03-31
0001465470
2021-04-01
2022-03-31
0001465470
us-gaap:NonrelatedPartyMember
2022-04-01
2023-03-31
0001465470
us-gaap:NonrelatedPartyMember
2021-04-01
2022-03-31
0001465470
us-gaap:RelatedPartyMember
2022-04-01
2023-03-31
0001465470
us-gaap:RelatedPartyMember
2021-04-01
2022-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2021-03-31
0001465470
us-gaap:CommonStockMember
2021-03-31
0001465470
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001465470
SHMP:StockToBeIssuedMember
2021-03-31
0001465470
SHMP:SubscriptionReceivableMember
2021-03-31
0001465470
us-gaap:RetainedEarningsMember
2021-03-31
0001465470
us-gaap:NoncontrollingInterestMember
2021-03-31
0001465470
2021-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-03-31
0001465470
us-gaap:CommonStockMember
2022-03-31
0001465470
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001465470
SHMP:StockToBeIssuedMember
2022-03-31
0001465470
SHMP:SubscriptionReceivableMember
2022-03-31
0001465470
us-gaap:RetainedEarningsMember
2022-03-31
0001465470
us-gaap:NoncontrollingInterestMember
2022-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:CommonStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2022-03-31
0001465470
SHMP:StockToBeIssuedMember
2021-04-01
2022-03-31
0001465470
SHMP:SubscriptionReceivableMember
2021-04-01
2022-03-31
0001465470
us-gaap:RetainedEarningsMember
2021-04-01
2022-03-31
0001465470
us-gaap:NoncontrollingInterestMember
2021-04-01
2022-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:CommonStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2023-03-31
0001465470
SHMP:StockToBeIssuedMember
2022-04-01
2023-03-31
0001465470
SHMP:SubscriptionReceivableMember
2022-04-01
2023-03-31
0001465470
us-gaap:RetainedEarningsMember
2022-04-01
2023-03-31
0001465470
us-gaap:NoncontrollingInterestMember
2022-04-01
2023-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-03-31
0001465470
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-03-31
0001465470
us-gaap:CommonStockMember
2023-03-31
0001465470
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001465470
SHMP:StockToBeIssuedMember
2023-03-31
0001465470
SHMP:SubscriptionReceivableMember
2023-03-31
0001465470
us-gaap:RetainedEarningsMember
2023-03-31
0001465470
us-gaap:NoncontrollingInterestMember
2023-03-31
0001465470
SHMP:HydrenesisLLCMember
2023-03-31
0001465470
SHMP:SeriesAConvertiblePreferredStockMember
2022-04-01
2023-03-31
0001465470
SHMP:SeriesERedeemableConvertiblePreferredStockMember
2022-04-01
2023-03-31
0001465470
SHMP:SeriesEConvertiblePreferredStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:SeriesFPreferredStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:WarrantMember
2023-03-31
0001465470
SHMP:SeriesAConvertiblePreferredStockMember
2021-04-01
2022-03-31
0001465470
SHMP:SeriesEConvertiblePreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:SeriesFPreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:ConvertibleDebtSecuritiesMember
2021-04-01
2022-03-31
0001465470
us-gaap:MeasurementInputSharePriceMember
2023-03-31
0001465470
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
2023-03-31
0001465470
us-gaap:MeasurementInputSharePriceMember
2022-03-31
0001465470
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
2022-03-31
0001465470
us-gaap:MeasurementInputExpectedTermMember
2022-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2023-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2023-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2022-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2022-03-31
0001465470
2022-11-04
2022-11-04
0001465470
2022-11-04
0001465470
us-gaap:DerivativeMember
2022-04-01
2023-03-31
0001465470
SHMP:WarrantsMember
2022-04-01
2023-03-31
0001465470
SHMP:PromissoryNoteMember
2022-04-01
2023-03-31
0001465470
us-gaap:BuildingMember
2023-03-31
0001465470
us-gaap:MachineryAndEquipmentMember
srt:MinimumMember
2023-03-31
0001465470
us-gaap:MachineryAndEquipmentMember
srt:MaximumMember
2023-03-31
0001465470
us-gaap:VehiclesMember
2023-03-31
0001465470
us-gaap:FurnitureAndFixturesMember
srt:MinimumMember
2023-03-31
0001465470
us-gaap:FurnitureAndFixturesMember
srt:MaximumMember
2023-03-31
0001465470
srt:ScenarioPreviouslyReportedMember
2021-04-01
2022-03-31
0001465470
srt:RestatementAdjustmentMember
2021-04-01
2022-03-31
0001465470
SHMP:PatentsPurchaseAgreementMember
SHMP:FAndTWaterSolutionsLLCMember
2021-05-19
0001465470
2018-03-01
2018-03-31
0001465470
SHMP:PatentsPurchaseAgreementMember
SHMP:FAndTWaterSolutionsLLCMember
2021-05-19
2021-05-19
0001465470
SHMP:PatentsPurchaseAgreementMember
SHMP:FAndTWaterSolutionsLLCMember
2021-05-19
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
2021-08-25
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:FirstDayOfNextCalendarMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:FirstDayOfEachSuccessiveCalendarMember
2022-04-01
2023-03-31
0001465470
SHMP:TechnologyRightsAgreementMember
SHMP:HydrenesisDeltaSystemsLLCMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:TechnologyRightsAgreementMember
SHMP:AtClosingMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:TechnologyRightsAgreementMember
SHMP:AfterClosingMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:TechnologyRightsAgreementMember
SHMP:UnrestrictedCommonSharesMember
2022-04-01
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
SHMP:TechnologyRightsAgreementMember
2023-03-31
0001465470
SHMP:TechnologyRightsAgreementMember
SHMP:HydrenesisDeltaSystemsLLCMember
2021-08-25
0001465470
SHMP:TechnologyRightsAgreementMember
SHMP:HydrenesisDeltaSystemsLLCMember
2021-08-25
2021-08-25
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
2021-04-01
2022-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
2023-03-31
0001465470
SHMP:HydrenesisDeltaSystemsLLCMember
2022-03-31
0001465470
SHMP:TechnologyRightsAgreementMember
2022-04-01
2023-03-31
0001465470
SHMP:TechnologyRightsAgreementMember
2021-04-01
2022-03-31
0001465470
SHMP:TechnologyRightsAgreementMember
2023-03-31
0001465470
SHMP:CapitalOneBankMember
2023-03-31
0001465470
SHMP:CapitalOneBankMember
2022-04-01
2023-03-31
0001465470
SHMP:CapitalOneBankMember
2022-03-31
0001465470
SHMP:ChaseBankMember
2023-03-31
0001465470
SHMP:ChaseBankMember
2022-04-01
2023-03-31
0001465470
SHMP:ChaseBankMember
2022-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2023-01-20
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2023-01-19
2023-01-20
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2022-08-17
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2022-08-16
2022-08-17
0001465470
srt:MaximumMember
2023-03-31
0001465470
2022-12-31
0001465470
SHMP:RestructuredAugustNoteMember
2022-04-01
2023-03-31
0001465470
SHMP:RestructuredAugustNoteMember
2023-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputSharePriceMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputPriceVolatilityMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputExpectedDividendRateMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:DebenturesSubjectToMandatoryRedemptionMember
2021-12-15
0001465470
us-gaap:CommonStockMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
2021-12-15
0001465470
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2022-02-07
0001465470
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
2021-12-15
0001465470
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
0001465470
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2022-04-01
2023-03-31
0001465470
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
2021-12-15
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputSharePriceMember
us-gaap:CommonStockMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputPriceVolatilityMember
2021-12-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember
us-gaap:MeasurementInputSharePriceMember
2021-12-15
0001465470
SHMP:AmendedAndRestatedSecuredPromissoryNoteMember
2022-11-04
2022-11-04
0001465470
SHMP:AmendedAndRestatedSecuredPromissoryNoteMember
2023-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
2023-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
2022-04-01
2023-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
2021-04-01
2022-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-03-31
0001465470
SHMP:RestructuredSeniorNoteMember
us-gaap:MeasurementInputSharePriceMember
2023-03-31
0001465470
SHMP:PromissoryNoteAMember
SHMP:VBFMember
2020-12-15
0001465470
SHMP:PromissoryNoteAMember
SHMP:VBFMember
2020-12-15
2020-12-15
0001465470
SHMP:PromissoryNoteBMember
SHMP:VBFMember
2020-12-15
0001465470
SHMP:PromissoryNoteBMember
SHMP:VBFMember
2020-12-15
2020-12-15
0001465470
SHMP:PromissoryNotesAandBMember
2021-12-23
0001465470
SHMP:PromissoryNotesAandBMember
2021-12-23
2021-12-23
0001465470
SHMP:WilliamsMember
SHMP:PromissoryNoteMember
2020-07-15
0001465470
SHMP:WilliamsMember
SHMP:PromissoryNoteMember
2020-07-15
2020-07-15
0001465470
SHMP:PromissoryNoteMember
SHMP:WilliamsMember
2023-03-31
0001465470
SHMP:PromissoryNoteMember
SHMP:WilliamsMember
2022-03-31
0001465470
SHMP:SeriesBPreferredEquityOfferingMember
SHMP:SecuritiesPurchaseAgreementMember
2021-05-19
2021-05-19
0001465470
SHMP:PatentsPurchaseAgreementMember
SHMP:FAndTWaterSolutionsLLCMember
2021-05-19
0001465470
SHMP:SeriesBPreferredEquityOfferingMember
SHMP:SecuritiesPurchaseAgreementMember
2021-05-19
0001465470
SHMP:FandTMember
2021-05-19
0001465470
SHMP:NASMember
2021-05-19
0001465470
SHMP:NASMember
2022-03-31
0001465470
us-gaap:SeriesAPreferredStockMember
2022-03-31
0001465470
us-gaap:SeriesBPreferredStockMember
2022-03-31
0001465470
us-gaap:SeriesDPreferredStockMember
2022-03-31
0001465470
us-gaap:SeriesEPreferredStockMember
2022-03-31
0001465470
us-gaap:SeriesEPreferredStockMember
2023-03-31
0001465470
us-gaap:SeriesBPreferredStockMember
2019-09-05
0001465470
us-gaap:SeriesBPreferredStockMember
2019-09-05
2019-09-05
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:GHSInvestmentsLLCMember
us-gaap:SeriesBPreferredStockMember
2019-09-17
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:GHSInvestmentsLLCMember
us-gaap:SeriesBPreferredStockMember
2019-09-17
2019-09-17
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:VariousTranchesMember
us-gaap:SeriesBPreferredStockMember
2020-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:VariousTranchesMember
us-gaap:SeriesBPreferredStockMember
2021-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesBPreferredStockMember
2020-04-01
2021-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:SeriesDPreferredStockMember
2020-12-16
0001465470
us-gaap:SeriesDPreferredStockMember
2020-12-16
2020-12-16
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2020-12-18
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2020-12-18
2020-12-18
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2021-01-10
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2021-01-08
2021-01-08
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2021-01-10
2021-01-10
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:PurchaserMember
us-gaap:SeriesDPreferredStockMember
2021-01-08
0001465470
SHMP:ShareExchangeAgreementMember
us-gaap:SeriesDPreferredStockMember
2021-04-15
2021-04-15
0001465470
us-gaap:SeriesEPreferredStockMember
2021-04-14
2021-04-14
0001465470
us-gaap:SeriesEPreferredStockMember
2021-04-14
0001465470
us-gaap:SeriesEPreferredStockMember
srt:MinimumMember
2021-04-14
2021-04-14
0001465470
us-gaap:SeriesEPreferredStockMember
srt:MaximumMember
2021-04-14
2021-04-14
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
2021-04-14
2021-04-14
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
srt:MaximumMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
2021-11-22
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
us-gaap:MeasurementInputPriceVolatilityMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
us-gaap:MeasurementInputExpectedDividendRateMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
2021-04-01
2022-03-31
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
2022-04-01
2023-03-31
0001465470
SHMP:ShareExchangeAgreementMember
us-gaap:SeriesDPreferredStockMember
2021-04-14
2021-04-14
0001465470
SHMP:ShareExchangeAgreementMember
us-gaap:SeriesDPreferredStockMember
2021-04-14
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesDPreferredStockMember
2021-04-14
2021-04-14
0001465470
SHMP:ShareExchangeAgreementMember
us-gaap:SeriesDPreferredStockMember
2021-04-01
2022-03-31
0001465470
us-gaap:SeriesEPreferredStockMember
2022-06-16
0001465470
2022-06-15
2022-06-16
0001465470
2022-06-16
2022-06-16
0001465470
2022-03-01
2022-03-01
0001465470
us-gaap:SeriesEPreferredStockMember
2022-04-01
2023-03-31
0001465470
us-gaap:SeriesEPreferredStockMember
2021-04-01
2022-03-31
0001465470
SHMP:GHSPurchaseAgreementMember
2022-11-03
2022-11-05
0001465470
2022-11-03
2022-11-05
0001465470
us-gaap:SeriesFPreferredStockMember
2022-02-22
0001465470
us-gaap:SeriesFPreferredStockMember
2022-02-22
2022-02-22
0001465470
SHMP:BoardOfDirectorsMember
us-gaap:SeriesFPreferredStockMember
2022-03-01
2022-03-01
0001465470
SHMP:BoardOfDirectorsMember
us-gaap:SeriesFPreferredStockMember
2022-03-01
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-04-14
2021-04-14
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-04-14
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-04-15
2021-04-15
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-05-05
2021-05-05
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-05-05
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-05-20
2021-05-20
0001465470
SHMP:SecuritiesPurchaseAgreementMember
2021-05-20
0001465470
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
SHMP:ExistingWarrantMember
2021-11-22
0001465470
SHMP:ExistingWarrantMember
SHMP:SecuritiesPurchaseAgreementMember
us-gaap:SeriesEPreferredStockMember
srt:MinimumMember
2021-11-22
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:GHSMember
2021-06-28
2021-06-28
0001465470
SHMP:SecuritiesPurchaseAgreementMember
SHMP:GHSMember
2021-06-28
0001465470
SHMP:GHSPurchaseAgreementMember
SHMP:GHSMember
2021-06-28
0001465470
SHMP:GHSPurchaseAgreementMember
SHMP:GHSMember
2021-06-28
2021-06-28
0001465470
SHMP:GHSPurchaseAgreementMember
2022-11-04
2022-11-04
0001465470
SHMP:GHSPurchaseAgreementMember
2022-11-04
0001465470
SHMP:ConsultantMember
2022-04-01
2023-03-31
0001465470
SHMP:ThreeConsultantsMember
2022-04-01
2023-03-31
0001465470
SHMP:ThreeConsultantsMember
srt:MinimumMember
2023-03-31
0001465470
SHMP:ThreeConsultantsMember
srt:MaximumMember
2023-03-31
0001465470
SHMP:ConsultantMember
2022-08-01
2022-08-01
0001465470
SHMP:ThreeConsultantsMember
2021-10-01
2021-12-31
0001465470
SHMP:ThreeConsultantsMember
2021-12-31
0001465470
SHMP:ConsultantMember
2021-04-14
2021-04-14
0001465470
SHMP:ConsultantMember
2021-04-14
0001465470
SHMP:ConsultantMember
2022-10-01
2022-10-01
0001465470
SHMP:ConsultantMember
SHMP:FirstSixMonthsMember
2021-05-24
2021-05-24
0001465470
SHMP:ConsultantMember
SHMP:PerMonthThereafterMember
2021-05-24
2021-05-24
0001465470
SHMP:ConsultantMember
2021-05-24
2021-05-24
0001465470
SHMP:ConsultantMember
2021-05-24
0001465470
SHMP:ConsultantMember
SHMP:VestedImmediatelyMember
2021-05-24
2021-05-24
0001465470
SHMP:ConsultantMember
SHMP:EachQuarterMember
2021-05-24
2021-05-24
0001465470
SHMP:ConsultantMember
SHMP:BusinessAgreementMember
2022-06-22
2022-06-22
0001465470
SHMP:NewEmployeesMember
2021-04-01
2022-03-31
0001465470
SHMP:NewEmployeesMember
2022-04-01
2023-03-31
0001465470
SHMP:NewEmployeesMember
2022-03-31
0001465470
2021-04-14
0001465470
2021-11-22
0001465470
2021-04-14
2021-04-14
0001465470
us-gaap:SeriesEPreferredStockMember
2021-11-22
2021-11-22
0001465470
us-gaap:SeriesEPreferredStockMember
2021-11-22
0001465470
us-gaap:SeriesEPreferredStockMember
2021-12-15
0001465470
srt:MinimumMember
2023-03-31
0001465470
us-gaap:MeasurementInputSharePriceMember
us-gaap:CommonStockMember
SHMP:BlackScholeModelMember
2023-03-31
0001465470
us-gaap:MeasurementInputRiskFreeInterestRateMember
SHMP:BlackScholeModelMember
2023-03-31
0001465470
us-gaap:MeasurementInputPriceVolatilityMember
SHMP:BlackScholeModelMember
2023-03-31
0001465470
us-gaap:MeasurementInputExpectedDividendRateMember
SHMP:BlackScholeModelMember
2023-03-31
0001465470
SHMP:ConsultingServicesMember
2021-04-01
2022-03-31
0001465470
srt:ChiefFinancialOfficerMember
2021-05-11
2021-05-11
0001465470
SHMP:PresidentAndChiefTechnicalOfficerMember
2021-08-10
0001465470
SHMP:PresidentAndChiefTechnicalOfficerMember
2021-04-01
2022-03-31
0001465470
SHMP:PresidentAndChiefTechnicalOfficerMember
2022-03-31
0001465470
SHMP:PresidentAndChiefTechnicalOfficerMember
2023-03-31
0001465470
2016-01-01
0001465470
SHMP:NotesPayableMember
2021-04-01
2022-03-31
0001465470
SHMP:NotesPayableMember
2022-04-01
2023-03-31
0001465470
SHMP:NotesPayableMember
2023-03-31
0001465470
SHMP:NotesPayableMember
2022-03-31
0001465470
SHMP:LoanAgreementMember
2022-08-09
2022-08-10
0001465470
SHMP:LoanAgreementMember
SHMP:PromissoryNotesMember
2022-08-10
0001465470
SHMP:LoanAgreementMember
SHMP:PromissoryNotesMember
2022-08-09
2022-08-10
0001465470
SHMP:PresidentsMember
us-gaap:RelatedPartyMember
2023-03-31
0001465470
SHMP:PresidentsMember
2022-04-01
2023-03-31
0001465470
SHMP:PresidentsMember
us-gaap:RelatedPartyMember
2022-03-31
0001465470
2014-12-31
0001465470
2021-08-01
2021-08-01
0001465470
2021-06-02
0001465470
2021-08-01
0001465470
2021-09-08
2021-09-08
0001465470
2021-09-08
0001465470
SHMP:AprilOneTwoThousandFifteenMember
2022-04-01
2023-03-31
0001465470
SHMP:AprilOneTwoThousandFifteenMember
SHMP:MrEasterlingMember
2021-05-04
2021-05-04
0001465470
2021-11-15
0001465470
us-gaap:CommonStockMember
SHMP:GaryShoverMember
2022-04-01
2023-03-31
0001465470
us-gaap:CommonStockMember
SHMP:MergerAgreementMember
2022-10-23
2022-10-24
0001465470
us-gaap:CommonStockMember
SHMP:MergerAgreementMember
2022-10-24
0001465470
SHMP:MergerAgreementMember
2022-10-23
2022-10-24
0001465470
SHMP:SeriesAConvertiblePreferredStockMember
2022-10-24
0001465470
SHMP:SeriesFConvertiblePreferredStockMember
2022-10-24
0001465470
SHMP:SeriesEConvertiblePreferredStockMember
2022-10-24
0001465470
SHMP:TwoThousandTwentyTwoPurchaseAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-04-01
2023-06-19
0001465470
SHMP:TwoThousandTwentyTwoPurchaseAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
srt:MinimumMember
2023-06-19
0001465470
SHMP:TwoThousandTwentyTwoPurchaseAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
srt:MaximumMember
2023-06-19
0001465470
SHMP:EquityFinancingAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-04-27
2023-04-28
0001465470
SHMP:EquityFinancingAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-04-28
0001465470
SHMP:GHSPurchaseAgreementMember
SHMP:GHSInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-05-08
2023-05-09
0001465470
us-gaap:SeriesEPreferredStockMember
us-gaap:SubsequentEventMember
2023-05-01
2023-05-01
0001465470
us-gaap:CommercialPaperMember
SHMP:YottaInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-04-21
0001465470
us-gaap:CommercialPaperMember
SHMP:YottaInvestmentLLCMember
us-gaap:SubsequentEventMember
2023-05-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SHMP:Integer
PART
I
ITEM
1. BUSINESS
As
used in this Annual Report on Form 10-K and unless otherwise indicated, the terms “NaturalShrimp,” “Company,” “we,” “us,”
and “our” refer to NaturalShrimp Incorporated and its wholly-owned subsidiaries: NaturalShrimp USA Corporation (“NSC”), NaturalShrimp Global, Inc. (“NS Global”) and Natural Aquatic Systems, Inc. (“NAS”). Unless otherwise specified,
all dollar amounts are expressed in United States Dollars.
Corporate
History
The
Company was incorporated in the State of Nevada on July 3, 2008 under the name “Multiplayer Online Dragon, Inc.” On January
30, 2015, we acquired substantially all of the assets of NaturalShrimp Holdings, Inc. (“NSH”), which had developed the proprietary technology
to grow and sell shrimp potentially anywhere in the world that is now the basis of our business. Such assets consisted primarily of all
of the issued and outstanding shares of capital stock of its subsidiaries NaturalShrimp Corporation, now called NaturalShrimp USA Corporation
(“NSC”), and NaturalShrimp Global (“NS Global”), and certain real property located outside of San Antonio, Texas,
in exchange for our issuance of 75,520,240 shares of NaturalShrimp common stock to NSH. As a result of the transaction, NSH acquired
88.62% of the issued and outstanding shares of NaturalShrimp common stock, NSC and NS Global became our wholly-owned subsidiaries, and
we changed our principal business to a global shrimp farming company. We changed our name to “NaturalShrimp Incorporated”
in 2015.
Business
Combination
On
October 24, 2022, the Company, Yotta Acquisition Corporation, a special purpose acquisition company (“Yotta”), and Yotta
Merger Sub, Inc., a Nevada corporation (“Merger Sub”) and wholly-owned subsidiary of Yotta, entered into a Merger
Agreement (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into the Company with the Company
as the surviving corporation of the Business Combination and becoming a wholly-owned subsidiary of Yotta (the “Business
Combination”). In connection with the Business Combination, Yotta will change its name to “NaturalShrimp
Incorporated” or such other name designated by the Company. We refer to Yotta after the Business Combination has been completed as the “Combined Company.”
At
the closing of the Business Combination, Yotta will issue 17.5 million shares of common stock to the former security holders of the
Company. In addition, the stockholders of the Company are entitled to receive an additional 5.0 million shares of Yotta’s
common stock based on achieving certain revenue targets for 2024 and 5 million shares of Yotta’s common stock based on
achieving certain revenue targets for 2025. In the event Yotta or the Company validly terminate the Merger Agreement because of a
default by the other, a breakup fee of $3.0 million will be due to the terminating party.
The
consummation of the Business Combination is conditioned upon customary closing conditions including the approval of the Merger Agreement
by the requisite vote of the Company’s stockholders and approval of the Merger Agreement and additional related matters by Yotta’s
stockholders.
Business
Overview
We
are an aquaculture technology company that has developed proprietary, patented platform technologies to allow for the production of aquatic
species in an ecologically-controlled, high-density, low-cost environment, and in fully contained and independent production facilities
without the use of antibiotics or toxic chemicals. NaturalShrimp owns and operates indoor recirculating Pacific White shrimp production
facilities in Texas and Iowa using these technologies.
On
October 5, 2015, together with F&T Water Solutions, LLC (“F&T”), we formed NAS,
with NaturalShrimp holding a majority interest. The purpose of NAS was for NaturalShrimp and F&T to jointly develop certain water
technologies including, without limitation, the electrocoagulation equipment dealing with enclosed aquatic production systems worldwide.
On
December 17, 2020, we acquired for $10,000,000 certain assets from VeroBlue Farms USA, Inc. (“VBF”) and its subsidiaries
VBF Transport, Inc. and Iowa’s First, Inc., which included facilities located in Webster City, Iowa, Blairsburg, Iowa, and
Radcliffe, Iowa. These facilities were designed for the growth of barramundi fish. We have converted 40% of the Webster City
facility and 20% of the Blairsburg facility for producing shrimp using the Company’s propriety technology.
On
May 25, 2021, the Company purchased from F&T its ownership interest in the water treatment technology that the Company and F&T
had previously jointly developed and patented (the “Patent”) through NAS, which is used or useful in growing aquatic species
in re-circulating and enclosed environments, as well as F&T’s 100% interest in a second patent associated with the Patent that
was issued to F&T in March 2018 and all other intellectual property rights owned by F&T. In addition, the Company acquired all
of the outstanding shares of common stock of NAS owned by F&T (the “Common Shares”), thereby making NAS a wholly-owned
subsidiary of the Company. The purchase price for both the Patent and the Common Shares totaled $3,000,000 in cash and 13,861,386 shares
of NaturalShrimp common stock valued at $7,000,000 for a total consideration of $10,000,000.
On
August 25, 2021, the Company, through its now wholly-owned subsidiary NAS, entered into an Equipment Rights Agreement with Hydrenesis
Delta Systems, LLC, and a Technology Rights Agreement with Hydrenesis Aquaculture, LLC, in a sub-license agreement with Hydrenesis Aquaculture
LLC. The Equipment Rights Agreements relates to specialized and proprietary equipment used to produce and control, dose, and infuse Hydrogas®
and RLS® into both water and other chemical species, while the Technology Rights Agreement provides us with a sublicense to the rights
to Hydrogas® and RLS®. These technologies enhance the health of the aquatic species and minimize stress in high ammonia conditions.
Each such agreement is for a 10-year term and automatically renew for successive 10-year terms unless terminated in accordance therewith.
The agreements give NAS the exclusive rights to purchase or distribute the technology, or buy or rent the equipment, in the Industry
Sector, which is the primary business and revenue stream generated from indoor aquaculture farming of any species in the Territory, defined
as anywhere in the world except for the countries in the Gulf Corporation Council. The Company paid Hydrenesis Delta Systems, LLC the sum of $2,500,000 (staged over a period of time, with $1,250,000
still due), plus a 12.5% royalty for the Equipment Rights Agreement and for the Technology Rights Agreement. The Company paid Hydrenesis
Aquaculture, LLC a total of $10,000,000, comprised of $2,500,000 at closing, $1,000,000 within 60 days and 6,500,000 shares of common
stock of the Company. The Technology Rights Agreement also carried the same royalty provision.
The
Company has three wholly-owned subsidiaries: NSC, NS Global, and NAS, and owns 51% of NaturalShrimp/Hydrenesis LLC, a Texas limited liability
company.
Development
of our Technology
General
Background and Overview
Historically,
efforts to raise shrimp in a high-density, closed system at the commercial level have been met with either modest success or outright
failure through “BioFloc Technology.” An aquaculture system using “BioFloc Technology” recycles waste nutrients
to culture microorganisms to form microbial protein from the toxic waste and other organic matter in the water. Infectious agents such
as parasites, bacteria, and viruses potentially present in BioFloc systems are the most damaging and most difficult to control. While
bacterial infection can in some cases be combated using antibiotics (although not always), the use of antibiotics is generally
considered undesirable and counter to “green” cultivation practices. Viruses can be worse in that they are immune to antibiotics.
Once introduced to a shrimp population, viruses can wipe out entire farms and shrimp populations, even with intense probiotic applications.
Our
primary solution against infectious agents is our “Vibrio Suppression Technology.” This technology utilizes electrocoagulation
(a procedure that uses heat from an electric current to destroy abnormal tissue) to kill potential pathogens and harmful bacteria such
aa vibrio. While bacteria and other pathogens can still survive using this technology, Vibrio Suppression Technology helps to
significantly reduce and suppress harmful organisms that usually cause “BioFloc” and other enclosed technologies to fail.
Based on several peer-reviewed studies as well as management’s experience with this technology, we believe that this system creates higher sustainable densities, consistent production, improved growth and survival rates,
and improved food conversion without the use of antibiotics, probiotics, or unhealthy anti-microbial chemicals.
Our
technology platforms combine electrocoagulation and Hydrogas. Our patented electrocoagulation system replaces the need for biofilters
and instead applies non-biological, electrical processes and uses electronics to remove ammonia and to control the level of pathogens
in an aquaculture system. These technologies generate water chemistry with antioxidant properties, as demonstrated by third-party studies
and our own trial conducted on North Atlantic Salmon at the RASLab research facility in Norway in 2021. The findings showed an increase
in the well-being of aquatic species, including enhanced growth rates.
Hydrogas
technology is based on a reducing gas that is produced on demand and infused into an aquaculture water column. The gas lowers the Oxidation
Reduction Potential (“ORP”) of water to a negative reading on an ORP meter. Negative ORP refers to the water’s ability to
either gain or lose electrons, acting as a measure of its reduction or oxidation capacity. When water has a negative ORP, it is more
prone to gaining electrons, indicating a higher reduction potential. The more negative the ORP value of the water column, the stronger
the reduction capacity, effects of which have been shown to have benefit within the aquaculture industry. The use of negative ORP water
in recirculating aquaculture systems can have several beneficial effects on the animals and their environment such as lowering of the
oxidation stress on the animals leading to better food conversion rates.
We
have conducted several internal tests over a period of two years with finfish and shrimp, where we observed decreased mortality rates
in the test groups utilizing the Hydrogas system.
The
use of electrocoagulation in Recirculating Aquaculture Systems (RAS) plays a pivotal role in achieving higher sustainable densities.
This technology utilizes an electrical current to coagulate particulates, bacteria, and other pollutants, leading to their precipitation
out of the water column. By removing these harmful elements, the water quality is significantly improved, which in turn can support higher
densities of animals without compromising their health and well-being. Furthermore, by reducing the bacterial load in the water, such
as harmful Vibrio species, the overall health and immunity of the aquaculture species can be boosted, resulting in lower disease incidences
and higher sustainable densities.
Maintaining
a negative ORP water column using Hydrogas not only aids in consistent production but also improves food conversion rates. A negative
ORP signifies a reducing environment, which is beneficial for lowering the oxidative stress on the animals, leading to better food conversion
rates. Moreover, the constant removal of harmful substances and bacteria from the water ensures a stable, high-quality environment for
the cultured species, leading to consistent growth rates and production. Thus, through the combined benefits of improved water quality,
enhanced health, and optimized nutrient utilization, electrocoagulation with a negative ORP water column serves as a valuable tool for
sustainable and efficient aquaculture systems.
The
principal theories behind the Company’s system are characterized as:
|
● |
High-density
shrimp production |
|
|
|
|
● |
Weekly
production |
|
|
|
|
● |
Natural
ecology system |
|
|
|
|
● |
Regional
production |
|
|
|
|
● |
Regional
distribution |
These
principles form the foundation for the Company and our potential distributors so that consumers can be provided with continuous volumes
of live and fresh shrimp at competitive prices.
Research
and Development; Evolution of Our Technology
In
2001, we began research and development of a high density, natural aquaculture system that is not dependent on ocean water to provide
quality, fresh shrimp every week, 52 weeks a year. Our initial system was successful, but we determined that it would not be economically
feasible due to high operating costs. Over the next several years, using the knowledge we gained from developing the first system, we
developed a shrimp production system that eliminated the high costs associated with the previous system. We have continued to refine
this technology, eliminating bacteria and other problems that affect recirculating systems, and now have a successful shrimp-growing
process. We have produced thousands of pounds of shrimp over the years in order to develop a design that will consistently produce quality
shrimp that grow to a large size at a specific rate of growth. This included experimenting with various types of natural live and synthesized
feed supplies before selecting the most appropriate nutritious and reliable combination. It also included utilizing monitoring and control
automation equipment to minimize labor costs and to provide the necessary oversight for proper regulation of the shrimp environment.
Our
system currently consists of a nursery tank where the shrimp are acclimated and then moved to a larger grow-out tank for the rest of
the growth cycle. During 2016, we engaged in additional engineering projects with third parties to further enhance our indoor production
capabilities. The Company, working with F&T, contracted with RGA Labs, Inc. to build and update a prototype of our patented electrocoagulation
system for the grow-out and harvesting of fully mature, antibiotic-free Pacific White shrimp. The design provided a viable pathway to
begin generating revenue and producing shrimp on a commercially-viable scale. During 2019 the Company decided to begin an approximately
$2,000,000 facility renovation, demolishing the interior wood-lined tanks (720,000 gallons). The Company began replacing the previous
tanks with 40 new fiberglass tanks (600,000 gallons) at a cost of approximately $400,000, allowing complete production flexibility with smaller tanks.
On
March 18, 2020, our research and development plant in La Coste, Texas was destroyed by a fire. The Company believed that it was caused
by a natural gas leak, but the fire was so extensive that the cause was never determined. No one was injured as a result of the fire.
The majority of the damage was to our pilot production plant, which comprised approximately 35,000 square feet of the total size of the
production facilities at the La Coste location, but the fire did not impact the separate greenhouse, reservoirs, or utility buildings.
The Company used the proceeds from its subsequent insurance claim to rebuild a 40,000 square foot production building at the La Coste
facility and to repurchase the equipment needed to replace what was lost in the fire. The Company further refined the electrocoagulation
system for installation in the Texas and later in its Iowa shrimp production facilities. The Company began making regular weekly sales
of live shrimp from the Iowa production facility in November 2021 and from the Texas production facility in June 2022.
Overview
of Industry
Shrimp
is a well-known and globally-consumed commodity, constituting one of the most important types of seafood and a staple protein source
for much of the world. According to the Food and Agriculture Organization of the United Nations, the 2021 global production of shrimp
was 9.9 billion pounds with over 1.9 billion pounds of shrimp consumed in the United States alone. Approximately 65% of the global supply
of shrimp is caught by ocean trawlers and the other 35% is produced by open-air shrimp farms, mostly in developing countries.
Shrimp
boats catch shrimp through the use of large, boat-towed nets. These nets are quite toxic to the undersea environment as they disturb
and destroy ocean-bottom ecosystems; these nets also catch a variety of non-shrimp sea life, which is typically killed and discarded
as part of the shrimp harvesting process. Additionally, the world’s oceans can only supply a finite amount of shrimp each year,
and in fact, single-boat shrimp yields have fallen by approximately 20% since 2010 and continue to decrease. The shrimping industry’s
answer to this problem has been to deploy more (and larger) boats that deploy ever-larger nets, which has in the short-term been successful
at maintaining global shrimp yields. This benefit, however, cannot continue forever, as eventually global demand has the potential of
outstripping the oceans’ ability to maintain the natural ecosystem’s balance, resulting in a permanent decline in yields.
When taken in light of global population growth and the ever-increasing demand for nutrient-rich foods such as shrimp, this method is
clearly an unsustainable production paradigm.
Shrimp
farming, known in the industry as “aquaculture,” has ostensibly stepped in to fill this demand/supply imbalance. Shrimp farming
is typically done in open-air lagoons and man-made shrimp ponds connected to the open ocean. Because these ponds constantly exchange
water with the adjacent sea, the farmers are able to maintain the water chemistry that allows the shrimp to prosper. This method of cultivating
shrimp, however, also carries severe ecological peril. First of all, most shrimp farming is primarily conducted in developing countries,
where poor shrimp farmers have little regard for the global ecosystem. As a result, these farmers use large quantities of antibiotics
and other chemicals that maximize each farm’s chance of producing a crop, putting the entire system at risk. For example, a viral
infection that crops up in one farm can spread to all nearby farms, quite literally wiping out an entire region’s production. In
1999, the White Spot virus invaded shrimp farms in at least five Latin American countries: Honduras, Nicaragua, Guatemala, Panama, and
Ecuador, and in 2013-14 Early Mortality Syndrome wiped out most of the shrimp yields in the Asia Pacific region and Mexico. Secondly,
there is also a finite amount of coastline that can be used for shrimp production — eventually shrimp farms that are dependent
on the open ocean will have nowhere to expand. Again, this method is also an ecologically damaging and ultimately unsustainable system
for producing shrimp.
In
both the cases, the current method of shrimp production is unsustainable. As global populations rise and the demand for shrimp continues
to grow, the current system is bound to fall short. Shrimp trawling cannot continue to increase production without completely depleting
the oceans’ natural shrimp population. Trends in per-boat yield confirm that this industry has already crossed the overfishing
threshold, putting the global open-ocean shrimp population in decline. While open-air shrimp aquaculture may seem to address this problem,
it is also an unsustainable system that destroys coastal ecological systems and produces shrimp with very high chemical contamination
levels. Closed-system shrimp farming is clearly a superior alternative, but its unique challenges have prevented it from becoming a widely-available
alternative.
Of
the 1.9 billion pounds of shrimp consumed annually in the United States, over 1.5 billion pounds are imported — much of this from
developing countries’ shrimp farms. These farms are typically located in developing countries and use high levels of antibiotics
and pesticides that are not allowed under USDA regulations. As a result, these shrimp farms produce chemical-laden shrimp in an ecologically
unsustainable way.
Unfortunately,
most consumers in the United States are not aware of the origin of their store-bought shrimp or the shrimp that they consume in restaurants.
This lack of knowledge is due to a USDA rule that states that only bulk-packaged shrimp must state the shrimp’s country of origin;
any “prepared” shrimp, which includes arrangements sold in grocery stores and seafood markets, as well as all shrimp served
in restaurants, can simply be sold “as is.” Essentially, the foregoing means that most U.S. consumers may be eating shrimp
laden with chemicals and antibiotics. Our product is free of pesticide chemicals and antibiotics, a fact that we believe will be highly
attractive and beneficial in terms of our eventual marketing success.
Target
Markets
We
are establishing three target markets. The first market is live shrimp delivered to grocery stores and placed in aquariums, the second
is fresh-on-ice shrimp delivered through distribution channels to groceries and restaurants, and the third is fresh-on-ice shrimp ordered
via an eCommerce website delivered directly to the consumer. Our goal is to establish production systems and distribution centers in
regional areas of the United States as well as international distribution networks through joint venture partnerships throughout the
world. This should allow the Company to capture a significant portion of world shrimp sales by offering locally-grown, environmentally-friendly,
fresh shrimp at competitive wholesale prices.
According
to the Food and Agriculture Organization of the United Nations, the United States consumed over 1.9 billion pounds of shrimp in 2021, second only to China in total consumption, with over 90% imported. According to Research and Markets, the worldwide
shrimp market was $18.3 billion in 2020 and is expected to reach $23.4 billion by 2026. According to SeafoodSource, in 2021 the United
States Food and Drug Administration (the “FDA”) refused 75 entry lines of antibiotic-contaminated shrimp, over twice as many
entry lines as was refused in 2020.
We
strive to build a profitable global shrimp production company. We believe that our foundational advantage is that we can deliver fresh,
organically grown, gourmet-grade shrimp, 52 weeks a year to retail and wholesale buyers in major market areas at competitive, yet premium,
prices. By locating regional production and distribution centers in close proximity to consumer demand, we can provide a fresh product
to customers within 24 hours after harvest. We believe that we can be the first to market and perhaps the sole weekly provider of fresh
shrimp. Based on existing demand and what we believe are the advantages of our process, we believe that we can capture as much market
share as our production capacity can support. The existing market demand, however, also might encourage new competitors to enter the
market, including competitors that might develop processes that directly compete with NaturalShrimp, which could result in our not being
able to capture the market share we anticipate.
Our
patented technology and eco-friendly, bio-secure production processes enable the delivery of a chemical and antibiotic-free, locally-grown
product that lives up to the Company’s mantra: “Always Fresh, Always Natural,” thereby addressing the issue of “unsafe”
imported seafood.
Our
Products
Product
Description
Most
of the shrimp consumed in the world today come from shrimp farms that can only produce crops between one and four times per year.
Consequently, the shrimp from these farms requires freezing between crops until consumed. Our system is designed to harvest
different tanks each week, which provides for fresh shrimp throughout the year. We strive to create a niche market of “Always
Fresh, Always Natural” shrimp. As opposed to many of the foreign shrimp farms, we can also claim that our product is 100% free
of antibiotics. The ability to grow shrimp locally and year-round allows us to provide this high-end product to upscale restaurant
and grocery stores throughout the world. The Company is currently selling live shrimp to grocery stores outlets in Chicago and to
stores and restaurants in Texas. We rotate the stocking and harvesting of our tanks each week, which allows for weekly shrimp
harvests. Our product is free of pollutants and is fed only the highest-quality feeds.
Shrimp
Growth Period
Our
production system will produce shrimp at a harvest size of 12 grams in 12 weeks for the live market and 25 grams in 20 weeks for the
fresh-on-ice market. We currently purchase post-larva shrimp that are approximately 10 days old. In the future, we plan to convert the
Blairsburg, Iowa facility into a hatchery to control the supply of shrimp to each of our facilities. Our full-scale production systems
include nursery and grow-out tanks, projected to produce fresh shrimp 52 weeks per year.
Distribution
and Marketing
We
plan to build environmentally friendly production systems near major metropolitan areas of the United States. Today, we have one, 40,000
square foot production facility in La Coste, Texas (near San Antonio) and three production facilities totaling 344,000 square feet in
Iowa. On January 4, 2021, the Company formed a limited liability company with Hydresnesis Aquaculture, LLC in order to negotiate with
local government for the construction of a production facility under available grant programs in Florida.
Because
our system is enclosed and also indoors, it is not affected by weather or climate and does not depend on ocean proximity. As such, we
believe that we will be able to provide, naturally grown, high-quality, fresh-never frozen shrimp to customers in major markets each
week. We believe that these characteristics will allow distribution companies that we partner with to leverage their existing customer
relationships by offering an uninterrupted supply of high-quality, fresh, and locally-grown shrimp. We plan to sell and distribute the
vast majority of our shrimp production through distributors, such as U.S. Foods in Texas markets, that have established customers and
sufficient capacity to deliver a fresh product within hours following harvest. We believe that we have the added advantage of being able
to market our shrimp as a fresh, natural, and locally-grown product using sustainable, eco-friendly technology, a key differentiation
from existing shrimp producers. Furthermore, we believe that our ability to advertise our product in this manner, along with the fact
that it is a locally-grown product, provides us with a marketing advantage over the competition. We expect to utilize distributors that
currently supply fresh seafood to upscale restaurants and supermarkets, country clubs, and retail stores whose clientele expect and appreciate
fresh, natural products.
Harvesting,
Packaging and Shipment
We
expect that each of our locations will include production, harvesting/processing and a general shipping and receiving area, in addition
to warehousing space for storage of necessary supplies and products required to grow, harvest, package, and otherwise make ready for
delivery, a fresh shrimp crop on a weekly basis to consumers in each individual market area within 24 hours following harvest.
The
seafood industry lacks a consistent source verification method to track seafood products as they move through countries and customs procedures.
With worldwide overfishing leading to declining shrimp freshness and sustainability around the world, it is vital for shrimp providers
to be able to realistically identify the source of their product. We have well-managed, sustainable facilities that are able to track
shrimp from hatchery to plate using environmentally responsible methods and intend to incorporate these methods in all our future facilities.
International
We
own 100% of NS Global, which was formed to create international partnerships and licensing for our platform technologies. Each international
partnership is expected to use the Company’s proprietary technology to penetrate shrimp markets throughout the world utilizing
existing food service distribution channels.
Go
to Market Strategy and Execution
Our
strategy is to acquire or develop regional production and distribution centers or joint ventures near major metropolitan areas throughout
the United States and internationally. Along with our La Coste facility that includes a 40,000 square foot production facility using a
new water treatment process. We have also purchased a 344,000 square foot production facilities and production assets from VBF. Our current plans include a NaturalShrimp Iowa expansion, a La Coste, Texas expansion, and Hydrenesis joint ventures while developing regional production
and distribution centers near major markets, adding production centers in Florida, Nevada, and New York.
We
have sold live product to grocery stores at $10.50 per pound and we have an exclusive agreement with U.S. Foods to distribute fresh-on-ice
shrimp weekly to retail consumers at $10.50 to $14.00 per pound depending on size, which helps to validate our pricing strategy. Additionally,
we are developing an eCommerce website for on-line ordering and home delivery by the name of NaturalShrimp Harvest-Select to provide
fresh-chilled directly to consumers at $22.00 per pound.
Current
Systems and Expansion
The
shrimp production facility rebuilt in La Coste, Texas is now using new patent-pending technologies the Company developed with F&T
and Hydrenesis. We expect this facility to produce approximately 6,000 pounds of shrimp every week. By staging the stocking and harvests
from tank to tank, it enables us to produce and therefore deliver fresh shrimp every week.
With
the purchase of our Iowa facilities from VBF, the Company is using the aforementioned platform technologies to retrofit 344,000 square
feet of the existing Iowa facilities that we expect will, once fully operational, produce 18,000 pounds of shrimp per week. We believe
that the combined output from our La Coste, Texas and Iowa facilities will be approximately 24,000 pounds of shrimp production per week
by the third or fourth calendar quarter of 2023.
The
regional production facilities to be located in Florida, Nevada, and New York are expected to begin construction from future
funding. These production centers are not surrounded by commercial shrimp production, and we believe that will create a high demand
for fresh shrimp in all of these locations. In addition, the Company will continue to use undeveloped land it owns in La Coste (37
acres) and Iowa (52 acres) to build as many systems as the Texas and our Midwest markets demand.
Competition
There
are a number of companies conducting research and development projects in their attempt to develop closed-system technologies in the
U.S., some with reported production and sales. Most North American shrimp farms are using a BioFloc System to intensify shrimp growth.
Since these are privately-held companies, it is not possible to know, with certainty, their state of technological development, production
capacity, need for water exchange, location requirements, financial status, and other matters. To the best of our knowledge, none are
producing significant quantities of shrimp relative to their local markets, and such fresh shrimp sales are likely confined to an area
near their production facility.
Additionally,
any new competitor would face significant barriers for entry into the market and would likely need years of research and development
to develop the proprietary technology necessary to produce similar shrimp at a commercially viable level. We believe that our technology
and business model set us apart from any current competition. It is possible that additional competitors will arise in the future, but
with the size and growth of the worldwide shrimp market, we are confident that many competitors could co-exist and thrive in the fresh
shrimp industry.
Intellectual
Property
The
following table provides information regarding our issued patents:
Patent
Document Number (Issued) |
|
Description |
|
Jurisdiction
|
|
Type |
|
Date
Filed |
|
Date
Issued |
|
Expiration
Date |
|
Current
Ownership |
|
Currently
In Active Use |
|
Must
Be In Continued Use |
|
Will
Be Maintained Until a Third-Party Challenge |
US
Patent 10,163,199 B2 |
|
Recirculating
Aquaculture System and Treatment method of Aquatic Species |
|
United
States |
|
Utility* |
|
11/28/2016 |
|
12/25/2018 |
|
11/28/2036 |
|
Natural
Shrimp Inc |
|
Yes |
|
Yes |
|
Yes |
US
Patent 11,297,809 B1 |
|
Ammonia
Control in a Recirculating Aquaculture System |
|
United
States |
|
Utility* |
|
7/7/2021 |
|
4/12/2022 |
|
7/7/2041 |
|
Natural
Shrimp Inc |
|
Yes |
|
Yes |
|
Yes |
US
Patent 9,908,794 B2 |
|
Electrocoagulation
Chamber with Atmospheric & Pressurized Flow Regimes |
|
United
States |
|
Utility* |
|
5/25/2015 |
|
3/6/2018 |
|
5/25/2035 |
|
Natural
Shrimp Inc |
|
Yes |
|
Yes |
|
Yes |
* |
Utility
patents are granted to anyone who invents or discovers any new and useful process, machine, article of manufacture, or compositions
of matters, or any new useful improvement thereof. |
Patent
Document Number (Applied) |
|
Description |
|
Jurisdiction |
|
Date
Filed |
Application
No 17/895,906 |
|
Method
and Apparatus for removing specific contaminants from water in a recirculating or linear treatment system |
|
United
States |
|
8/25/2022 |
Trademarks |
|
Jurisdiction |
|
Live |
|
First
Used in Commerce |
|
Date
Filed |
|
Published
for Opposition |
|
Registration
Date |
|
Word
Mark |
|
Currently
In Active Use |
|
Must
Be In Continued Use |
|
Will
Be Maintained Until a Third Party Challenge |
6,122,073 |
|
United
States |
|
Yes |
|
12/31/2004 |
|
7/2/2019 |
|
5/26/2020 |
|
8/11/2022 |
|
NATURALSHRIMP |
|
Yes |
|
Yes |
|
Yes |
We
intend to take appropriate steps to protect our intellectual property.
There
are potential additional technical processes for which the Company may be able to file a patent. There are no assurances, however, that
such applications, if filed, would be issued and no right of enforcement is granted to a patent application. Therefore, the Company plans
to use a variety of other methods, including copyright registrations as appropriate, trade secret protection, and confidentiality and
non-compete agreements to protect its intellectual property portfolio.
Source
and Availability of Raw Materials
We
receive necessary raw materials from established suppliers, generally in a timely manner. Currently, we buy our feed from Zeigler, a
leading producer of aquatic feed. Post larvae shrimp are available from Sea Products Development in Texas and Homegrown Shrimp in Florida.
Notwithstanding
our current relationship with our suppliers of Post Larvae (PLs) shrimp, we have previously experienced temporary shortages and delays
as a result issues arising at their hatcheries. We have favorable contacts and past business dealings with other major shrimp feed producers
from which we can purchase required raw materials if our current suppliers are not available. In addition, we have also experienced supply-chain
problems that have restricted our access to needed equipment parts and supplies. However, we have been able to mitigate these issues
by modifying off-the-shelf readily available parts and equipment to work within our system.
Government
Approvals and Regulations
We
are subject to government regulation and require certain licenses. The following list includes regulations to which we are subject and/or
the permits and licenses we currently hold:
|
● |
Exotic
Species Permit (annual) required and issued by the Texas Parks and Wildlife Department (“TPWD”) relating to operation
of the Company’s facility in La Coste, Texas to raise exotic shrimp (non-native to Texas). This permit is currently active,
expiring on December 31, 2023. |
|
● |
Annual
permit issued by the Texas Commission on Environmental Quality (“TCEQ”). TCEQ regulates facility wastewater discharge.
The La Coste facility is rated Level 1 (Recirculation System with No Discharge). The Company’s technologies provide for zero
discharge, which makes it much easier to locate production facilities in various locations having strict environmental requirements. |
|
● |
The
Company has applied to register the La Coste facility with the FDA in case the Company decides to process the shrimp in the future
at this facility. However, the shrimp are currently delivered heads-on with no processing. |
|
● |
The
Company has applied to register the facility in Webster City, Iowa with the FDA in case the Company decides to process the shrimp
in the future at this facility. However, the shrimp are currently delivered heads-on with no processing. |
|
● |
Annual
aquaculture license issued by Iowa Department of Natural Resources in respect of the Webster City, Iowa facility to produce shrimp
in Iowa. |
We
are subject to certain regulations regarding the need for field employees to be certified. We strictly adhere to these regulations. The
cost of certification is an accepted part of expenses. Regulations may change and become a cost burden, but compliance and safety are
our main concern.
Market
Advantages and Corporate Drivers
We
consider the following to be our advantages in the marketplace:
|
● |
Early-mover
Advantage: We believe that we have an early-mover advantage via commercialized platform technologies in a large, growing market
with no significant competition yet identified. Most potential competitors are early-stage companies with limited production and
distribution. |
|
● |
Farm-to-Market:
This factor has significant advantages including reduced transportation costs and a product that we believe is more attractive to
local consumers. |
|
● |
Bio-secured
Building: Our process is a re-circulating, highly-filtered water technology in an indoor-regulated environment. External pathogens
are excluded. |
|
● |
Eco-friendly
Technology: Our closed-loop, recirculating system has no ocean water exchange requirements, does not use chemical or antibiotics
and therefore is sustainable, eco-friendly, environmentally sound, and produces a superior-quality shrimp that is totally natural. |
|
● |
Availability
of Weekly Fresh Shrimp: Assures consumers of optimal freshness, taste, and texture of product, which we believe will command
premium prices. |
|
● |
Sustainability:
Our naturally grown product does not deplete wild supplies, has no by-catch kill of marine life, does not damage sensitive ecological
environments, and avoids potential risks of imported seafood. |
Although
we have the patented technology and concomitant trade secrets necessary to grow shrimp in commercial quantities in a recirculating, enclosed
system, and believe that we have significant advantages in this market, we face competitive challenges from various directions. As noted
above, the market for fresh shrimp is significant and attractive and could potentially lead to the development of new technologies that
may compete with ours or copycat technologies that infringe on our patents and/or trade secrets.
Outside
forces over which we have no control, such as supply chain issues, may create unforeseen obstacles that could hinder our ability to meet
production goals. Further, weather may damage those companies from whom we purchase post-larvae shrimp and prohibit us from satisfying
its contractual commitments to third party purchasers of our shrimp. Further, there might not be a sufficient pool of potential employees
with the technical education and skills we require to staff and operate our intended new facilities in the locations in which we intend
to expand.
Diversity,
Equity and Inclusion
Much
of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels. We believe
that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive
and positive culture based on our shared mission and values.
Environmental,
Social and Governance
Our
commitment to integrating sustainability across our organization begins with our Board of Directors, or the Board. The Nominating and
Governance Committee of the Board has oversight of strategy and risk management related to Environmental, Social and Governance, or ESG.
All employees are responsible for upholding our core values, including to communicate, collaborate, innovate and be respectful, as well
as for adhering to our Code of Ethics and Business Conduct, including our policies on bribery, corruption, conflicts of interest and
our whistleblower program. We encourage employees to come to us with observations and complaints, ensuring we understand the severity
and frequency of an event in order to escalate and assess accordingly. Our Chief Compliance Officer strives to ensure accountability,
objectivity, and compliance with our Code of Conduct. If a complaint is financial in nature, the Audit Committee Chair is notified concurrently,
which triggers an investigation, action, and report.
We
are committed to protecting the environment and attempt to mitigate any negative impact of our operations. We monitor resource use, improve
efficiency, and at the same time, reduce our emissions and waste. We are systematically addressing the environmental impacts of the buildings
we rent as we make improvements, including adding energy control systems and other energy efficiency measures. Waste in our own operation
is minimized by our commitment to reduce both single-use plastics and operating paper-free, primarily in a digital environment. We have
safety protocols in place for handling biohazardous waste in our labs, and we use third-party vendors for biohazardous waste and chemical
disposal.
Corporate
and Available Information
Our
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports are available
free of charge though our website (http://www.naturalshrimp.com) as soon as practicable after such material is electronically filed with,
or furnished to, the Securities and Exchange Commission (the “SEC”). Except as otherwise stated in these documents, the information
contained on our website or available by hyperlink from our website is not incorporated by reference into this report or any other documents
we file, with or furnish to, the SEC.
Human
Capital Management
Employees
As
of March 31, 2023, we had 32 employees, 28 of whom were full-time employees. In addition, we retain the services of outside consultants
for various functions including engineering, finance, accounting and business development services. None of our employees are covered
by collective bargaining agreements. We believe that we have good relations with our employees. We believe that our future success will
depend, in part, on our continued ability to attract, hire, and retain qualified personnel. In particular, we depend on the skills, experience,
and performance of our senior management and engineering and technical personnel. We compete for qualified personnel with other aquaculture
industries.
We
provide competitive compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs
(which vary by country/region and employment classification) include incentive compensation plan, pension, healthcare and insurance benefits,
paid time off, family leave, and on-site services, among others. We also use targeted equity-based grants with vesting conditions to
facilitate retention of personnel, particularly for our key employees.
Contractors
As
of March 31, 2023, we retain 13 consultants and independent contractors.
ITEM
1A. RISK FACTORS
You
should carefully consider the risks described below together with all of the other information included in our public filings before
making an investment decision with regard to our securities. The statements contained in this document that are not historic facts are
forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those
set forth in or implied by forward-looking statements. If any of the following events described in these risk factors actually occur,
our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could
decline, and you may lose all or part of your investment. Moreover, additional risks not presently known to us or that we currently deem
less significant also may impact our business, financial condition, or results of operations, perhaps materially. For additional information
regarding risk factors, see “Forward-Looking Statements.”
Risks
Related to Our Business and Industry
The
market for our product may be limited, and as a result our business may be adversely affected.
The
feasibility of marketing our product has been assumed to this point and there can be no assurance that such assumptions are correct.
It is possible that the costs of development and implementation of our shrimp production technology may be too expensive to market our
shrimp at a competitive price. It is likewise possible that competing technologies will be introduced into the marketplace before or
after the introduction of our product to the market, which may affect our ability to market our product at a competitive price.
Furthermore,
there can be no assurance that the prices we determine to charge for our product will be commercially acceptable or that the prices that
may be dictated by the market will be sufficient to provide to us sufficient revenues to profitably operate and provide a financial return
to our investors.
Our
business and operations are affected by the volatility of prices for shrimp.
Our
business, prospects, revenues, profitability, and future growth are highly dependent upon the prices of and demand for shrimp. Our ability
to borrow and to obtain additional capital on attractive terms is also substantially dependent upon shrimp prices. These prices have
been and are likely to continue to be extremely volatile for seasonal, cyclical, and other reasons. Any substantial or extended decline
in the price of shrimp will have a material adverse effect on our financing capacity and our prospects for commencing and sustaining
any economic commercial production. In addition, increased availability of imported shrimp can affect our business by lowering commodity
prices. This could reduce the value of inventories, held both by us and by our customers, and cause many of our customers to reduce their
orders for new products until they can dispose of their higher-cost inventories.
Market
demand for our products may decrease.
We
face competition from other producers of seafood as well as from other protein sources, such as pork, beef, and poultry. The bases on
which we expect to compete include, but may not be limited to:
● |
price; |
● |
product
quality; |
● |
brand
identification; and |
● |
customer
service. |
Demand
for our products will be affected by our competitors’ promotional spending. We may be unable to compete successfully on any or
all of these bases in the future, which may have a material adverse effect on our revenues and results of operations.
Moreover,
although historically the logistics and perishability of seafood has led to regionalized competition, the market for fresh and frozen
seafood is becoming increasingly globalized as a result of improved delivery logistics and improved preservation of the products. Increased
competition, consolidation, and overcapacity may lead to lower product pricing of competing products that could reduce demand for our
products and have a material adverse effect on our revenues and results of operations.
Competition
and unforeseen limited sources of supplies in the industry may result in occasional spot shortages of equipment, supplies, and materials.
In particular, we may experience possible unavailability of post-larvae and materials and services used in our shrimp production facilities.
Such unavailability could result in increased costs and delays to our operations. If we cannot find the products, equipment, supplies,
and materials that we need on a timely basis, we may have to suspend our production plans until we find the products, equipment, and
materials that we need.
Our
expansion plans for our shrimp production facilities reflects our current intent and is subject to change.
Our
current expansion plans are subject to change, and the continuance of such plans will depend on the following factors, among others:
● |
availability
and cost of capital; |
● |
current
and future shrimp prices; |
● |
costs
and availability of post-larvae shrimp, equipment, supplies, and personnel necessary to conduct these operations; |
● |
the
success or failure of system design and activities in similar areas; |
● |
changes
in the estimates of the costs to complete production facilities; and |
● |
the
decisions of operators and future joint venture partners. |
We
will continue to gather data about our production facilities, and it is possible that additional information may cause us to alter our
schedule or determine that a certain facility should not be pursued at all.
Our
product is subject to regulatory approvals and if we fail to obtain such approvals, our business may be adversely affected.
Most
of the jurisdictions in which we operate will require us to obtain a license for each facility that we own and operate in that jurisdiction.
We have obtained and currently hold a license to own and operate each of our facilities where a license is required. In order to maintain
the licenses, we have to operate our current farms and, if we pursue acquisitions or construction of new farms, we will need to obtain
additional licenses to operate those farms, where required. We are also exposed to dilution of the value of our licenses where a government
issues new licenses to fish farmers other than us, thereby reducing the current value of our fish-farming licenses. Governments may change
the way licenses are distributed or otherwise dilute or invalidate our licenses. If we are unable to maintain or obtain new fish-farming
licenses or if new licensing regulations dilute the value of our licenses, this may have a material adverse effect on our business.
It
is possible that regulatory authorities could make changes in regulatory rules and policies, and we would not be able to market or commercialize
our product in the intended manner and/or the changes could adversely impact the realization of our technology or market potential.
Failure
to ensure food safety and compliance with food safety standards could result in serious adverse consequences for us.
As
our end products are for human consumption, food safety issues (both actual and perceived) may have a negative impact on the reputation
of and demand for our products. In addition to the need to comply with relevant food safety regulations, it is of critical importance
that our products are safe and perceived as safe and healthy in all relevant markets.
Our
products may be subject to contamination by food-borne pathogens, such as Listeria monocytogenes, Clostridia, Salmonella and E. Coli
or contaminants. As these pathogens and substances are found in the environment, there is a risk that one or more of these organisms
and pathogens can be introduced into our products as a result of improper handling, poor processing hygiene, or cross-contamination by
us, the ultimate consumer, or any intermediary. We have little, if any, control over handling procedures once we ship our products for
distribution. Furthermore, we may not be able to prevent contamination of our shrimp by pollutants such as polychlorinated biphenyls,
or PCBs, dioxins, or heavy metals.
An
inadvertent shipment of contaminated products may be a violation of law and may lead to product liability claims, product recalls (which
may not entirely mitigate the risk of product liability claims), increased scrutiny, and penalties, including injunctive relief and plant
closings, by regulatory agencies, as well as adverse publicity.
Increased
quality demands from authorities in the future relating to food safety may have a material adverse effect on our business, financial
condition, results of operations, or cash flow. Legislation and guidelines with tougher requirements are expected and may imply higher
costs for the food industry. In particular, the ability to trace products through all stages of development, certification, and documentation
is becoming increasingly required under food safety regulations. Further, limitations on additives and use of medical products in the
farmed shrimp industry may be imposed, which could result in higher costs for us.
The
food industry, in general, experiences high levels of customer awareness with respect to food safety and product quality, information,
and traceability. We may fail to meet new and exacting customer requirements, which could reduce demand for our products.
Our
success is dependent upon our ability to commercialize our shrimp production technology.
Prior
to fiscal year 2021, we had been engaged primarily in the research and development of our technology. Therefore, we have a limited operating
history upon which current and potential investors can evaluate our prospects. Our prospects must be considered in light of the risk,
uncertainties, expenses, delays, and difficulties associated with the establishment of a business in the evolving food industry, as well
as those risks encountered in the shift from development to commercialization of new technology and products or services based upon such
technology.
While
we have developed our first commercial system that employs our technology, additional work is required to incorporate that technology
into a system capable of accommodating thousands of customers, which is the minimum capability that we believe is necessary to compete
in the marketplace.
Our
shrimp production technology may not operate as intended.
Although
we have successfully tested our technology, our approach, which is still fairly new in the industry, may not operate as intended or may
be subject to other factors that we have not yet considered. These may include the impact of new pathogens or other biological risks,
low oxygen levels, algal blooms, fluctuating seawater temperatures, predation, or escapes. Any of the foregoing may result in physical
deformities to our shrimp or affect our ability to increase shrimp production, which may have a material adverse effect on our operations.
Furthermore, even if we are able to successfully manage these factors, our ability to grow healthy shrimp at a commercially scalable
rate may be limited.
Our
success is dependent upon our ability to protect our intellectual property.
Our
success will depend in part on our ability to obtain and enforce protection for our intellectual property in the United States and other
countries. It is possible that our intellectual property protection could fail. It is possible that the claims for patents or other intellectual
property protections could be denied or invalidated or that our protections will not be sufficiently broad to protect our technology.
It is also possible that our intellectual property will not provide protection against competitive products or will not otherwise be
commercially viable.
Our
commercial success will depend in part on our ability to commercialize our shrimp production without infringing on patents or proprietary
rights of others. We cannot guarantee that other companies or individuals have not or will not independently develop substantially equivalent
proprietary rights or that other parties have not or will not be issued patents that may prevent the sale of our products or require
licensing and the payment of significant fees or royalties in order for us to be able to carry on our business.
We
will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
As
our business strategies develop, we must add additional managerial, operational, financial, and other personnel. Future growth will impose
significant added responsibilities on members of management, including:
● |
identifying,
recruiting, integrating, maintaining, and motivating additional personnel; |
● |
managing
our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties;
and |
● |
improving
our operational, financial and management controls, reporting systems, and procedures. |
Our
future financial performance will depend, in part, on our ability to effectively manage any future growth and our management may also
have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of
time to managing these growth activities.
We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors,
and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors,
and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition,
if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants
is compromised for any reason, we may not be able to advance our business. There can be no assurance that we will be able to manage our
existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. If we are
not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may
not be able to successfully implement the tasks necessary to further develop our business initiatives and, accordingly, may not achieve
our research, development, and commercialization goals.
These
and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain
profitable operations.
Risks
Related to Financing Our Business
Management
has determined that there are factors that raise substantial doubt about our ability to continue as a going concern.
The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America, assuming we will continue as a going concern, which contemplates the realization of assets and satisfaction
of liabilities in the normal course of business. For the fiscal year ended March 31, 2023, we had a net loss available for common stockholders
of approximately $17.5 million. At March 31, 2023, we had an accumulated deficit of approximately $167.5 million and a working capital
deficit of approximately $9.3 million. These factors raise substantial doubt about our ability to continue as a going concern, within
one year from the issuance date of this report. Our ability to continue as a going concern is dependent on our ability to raise the required
additional capital or debt financing to meet short and long-term operating requirements. We may also encounter business endeavors that
require significant cash commitments or unanticipated problems or expenses that could result in a requirement for additional cash. As
we continue to raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our
current stockholders could be reduced, and such securities might have rights, preferences, or privileges senior to our common stock.
Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available to us or are not available
on acceptable terms, we may not be able to take advantage of prospective business endeavors or opportunities, which could significantly
and materially restrict our operations. If we are unable to obtain the necessary capital, we may have to cease operations.
The
rebuilding and expansion of our operations in Webster City, Iowa will require significant capital expenditures for which we may be unable
to obtain sufficient financing.
Our
need for additional capital may adversely affect our financial condition. Even prior to the loss of our plant in La Coste by fire or
the purchase of the VBF assets in Webster City, Iowa, we had no sustained history of earnings and have operated at a loss since we commenced
business. We have relied, and continue to rely, on external sources of financing to meet our capital requirements, to continue developing
our proprietary technology, to build our production facilities, and to otherwise implement our corporate development and investment strategies.
We
plan to obtain the future funding that we will need through the debt and equity markets, but there can be no assurance that we will be
able to obtain additional funding when it is required. If we fail to obtain the funding that we need when it is required, we may have
to forego or delay potentially valuable opportunities to build shrimp production facilities or default on existing funding commitments
to third parties. Our limited operating history may make it difficult to obtain financing in the future.
Our
ability to generate positive cash flows is uncertain.
To
develop and expand our business, we will need to make significant up-front investments in our manufacturing capacity and incur research
and development, sales and marketing, and general and administrative expenses. In addition, our growth will require a significant investment
in working capital. Our business will require significant amounts of working capital to meet our production requirements and support
our growth.
We
cannot provide any assurance that we will be able to raise the capital necessary to meet these requirements. If adequate funds are not
available or are not available on satisfactory terms, we may be required to significantly curtail our operations and may not be able
to fund our production requirements once they commence - let alone fund expansion, take advantage of unanticipated acquisition opportunities,
develop, or enhance our products, or respond to competitive pressures. Any failure to obtain such additional financing could have a material
adverse effect on our business, results of operations, and financial condition.
We
have a history of operating losses and anticipate future losses and may never be profitable.
We
have experienced significant operating losses in each period since we began investing resources in our production of shrimp. These losses
have resulted principally from research and development, sales and marketing, and general and administrative expenses associated with
the development of our business. During the fiscal year ended March 31, 2023, we recorded a net loss available for common stockholders
of approximately $17.5 million, or $0.02 per share, as compared with approximately $96.4 million, or $0.16 per share, for the year
ended March 31, 2022. We expect to continue to incur operating losses until we reach sufficient commercial scale of our product to cover
our operating costs. We cannot be certain when, if ever, we will become profitable. Even if we were to become profitable, we might not
be able to sustain such profitability on a quarterly or annual basis.
Because
we may never have net income from our operations, our business may fail.
We
have no history of revenues and profitability from operations. There can be no assurance that we will ever operate profitably. Our success
is significantly dependent on uncertain events, including successful development of our technology, establishing satisfactory manufacturing
arrangements and processes, and distributing and selling our products.
Before
receiving revenues from sales to customers of our products, we anticipate that we will incur increased operating expenses without realizing
any revenues. We therefore expect to incur significant losses. If we are unable to generate significant revenues from sales of our products,
we will not be able to earn profits or continue operations. We can provide no assurance that we will generate any revenues or ever achieve
profitability. If we are unsuccessful in addressing these risks, our business will fail, and investors may lose all of their investment
in our Company.
Our
insurance coverage may be inadequate to cover all significant risk exposures.
We
will be exposed to particular and heightened liabilities as a result of the products we provide. As our products are intended to be ingested
by natural persons, we have a heightened level of liability because a problem with our product is more likely to cause injury than many
other consumer products. In addition, seafood in particular has a higher risk of contamination or causing food-borne illness than many
other types of foods. While we intend to maintain insurance, the amount of our insurance coverage may not be adequate to cover all claims
or liabilities, and we may be forced to bear substantial costs resulting from risks and uncertainties of our business. It is also not
possible to obtain insurance to protect against all operational risks and liabilities. The failure to obtain adequate insurance coverage
on terms favorable to us, or at all, could have a material adverse effect on our business, financial condition, and results of operations.
We do not have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and
diversion of resources.
Our
margins fluctuate, which leads to further uncertainty in our profitability model.
While
we will have the potential ability to negotiate prices that benefit our clients and affect our profitability as it garners market-share
and increases our book of business, margins in the aquaculture business are fluid, and our margins vary based upon production volume
and the customer. This may lead to continued uncertainty in margins from quarter to quarter.
Risks
Related to Doing Business in Foreign Countries
Our
operations in foreign countries are subject to political, economic, legal, and regulatory risks.
The
following aspects of political, economic, legal, and regulatory systems in foreign countries create uncertainty with respect to many
of the legal and business decisions that we make:
● |
cancellation
or renegotiation of contracts due to uncertain enforcement and recognition procedures of judicial decisions; |
● |
disadvantages
of competing against companies from countries that are not subject to U.S. laws and regulations, including the Foreign Corrupt Practices
Act; |
● |
changes
in foreign laws or regulations that adversely impact our business; |
● |
uncertainty
regarding tariffs that may be imposed against certain international countries from time-to-time; |
● |
changes
in tax laws that adversely impact our business, including, but not limited to, increases in the tax rates and retroactive tax claims; |
● |
royalty
and license fee increases; |
● |
expropriation
or nationalization of property; |
● |
currency
fluctuations; |
● |
foreign
exchange controls; |
● |
import
and export regulations; |
● |
changes
in environmental controls; |
● |
business
interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks (such as the outbreak
of COVID-19); |
● |
risks
of loss due to civil strife, acts of war and insurrection; and |
● |
other
risks arising out of foreign governmental sovereignty over the areas in which our operations are conducted. |
Consequently,
our development and production activities in foreign countries may be substantially affected by factors beyond our control, any of which
could materially adversely affect our business, prospects, financial position, and results of operations. Furthermore, in the event of
a dispute arising from our operations in other countries, we may be subject to the exclusive jurisdiction of courts outside the United
States or may not be successful in subjecting non-U.S. persons or entities to the jurisdiction of the courts in the United States, which
could adversely affect the outcome of a dispute.
The
cost of complying with governmental regulations in foreign countries may adversely affect our business operations.
We
may be subject to various governmental regulations in foreign countries. These regulations may change depending on prevailing political
or economic conditions. In order to comply with these regulations, we believe that we may be required to obtain permits for producing
shrimp and file reports concerning our operations. These regulations affect how we carry on our business, and in order to comply with
them, we may incur increased costs and delay certain activities pending receipt of requisite permits and approvals. If we fail to comply
with applicable regulations and requirements, we may become subject to enforcement actions, including orders issued by regulatory or
judicial authorities requiring us to cease or curtail our operations or take corrective measures involving capital expenditures, installation
of additional equipment, or remedial actions. We may be required to compensate third parties for loss or damage suffered by reason of
our activities and may face civil or criminal fines or penalties imposed for violations of applicable laws or regulations. Amendments
to current laws, regulations, and permit requirements governing our operations and activities could affect us in a materially adverse
way and could force us to increase expenditures or abandon or delay the development of shrimp production facilities.
Our
international operations will involve the use of foreign currencies, which will subject us to exchange rate fluctuations and other currency
risks.
We
currently have no revenues from international operations. In the future, however, any revenues and related expenses of our international
operations will likely be generally denominated in local currencies, which will subject us to exchange rate fluctuations between such
local currencies and the U.S. dollar. These exchange rate fluctuations will subject us to currency translation risk with respect to the
reported results of our international operations, as well as to other risks sometimes associated with international operations. In the
future, we could experience fluctuations in financial results from our operations outside of the United States, and there can be no assurance
we will be able, contractually or otherwise, to reduce the currency risks associated with our international operations.
Risks
Related to Ownership of our Common Stock
We
have limited capitalization and may require financing, which may not be available.
We
have limited capitalization, which increases our vulnerability to general adverse economic and industry conditions, limits our flexibility
in planning for or reacting to changes in our business and industry and may place us at a competitive disadvantage to competitors with
sufficient or excess capitalization. If we are unable to obtain sufficient financing on satisfactory terms and conditions, we will be
forced to curtail or abandon our plans or operations. Our ability to obtain financing will depend upon a number of factors, many of which
are beyond our control.
The
trading of our common stock may have liquidity fluctuations.
Although
our common stock is listed for quotation on the OTCQB, under the symbol “SHMP”, and the trading volume of our stock has increased
significantly over the last three calendar years, such liquidity may not continue to be sustainable. As a result, any trading price of
our common stock may not be an accurate indicator of the valuation of our common stock. Any trading in our shares could have a significant
effect on our stock price. If the public market for our common stock declines, then investors may not be able to resell the shares of
our common stock that they have purchased and may lose all of their investment. No assurance can be given that an active market will
continue or that a stockholder will be able to liquidate their shares of common stock without considerable delay, if at all. Furthermore,
our stock price may be impacted by factors that are unrelated or disproportionate to our operating performance. These market fluctuations,
as well as general economic, political and market conditions, such as recessions, interest rates or international currency fluctuations
may adversely affect the market price and liquidity of our common stock.
Our
stock price may be volatile.
The
market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors,
many of which are beyond our control, including the following:
● |
actual
or anticipated variations in our quarterly operating results; |
● |
changes
in our business or potential earnings estimates; |
● |
our
ability to obtain adequate working capital financing; |
● |
changes
in market valuations of similar companies; |
● |
publication
(or lack of publication) of research reports about us; |
● |
changes
in applicable laws or regulations, court rulings, enforcement, and legal actions; |
● |
loss
of any strategic relationships; |
● |
additions
or departures of key management personnel; |
● |
actions
by our stockholders (including transactions in our shares); |
● |
speculation
in the press or investment community; |
● |
increases
in market interest rates, which may increase our cost of capital; |
● |
changes
in our industry; |
● |
competitive
pricing pressures; |
● |
the
impact of COVID-19; |
● |
our
ability to execute our business plan; and |
● |
economic
and other external factors. |
In
addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the
operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of
our common stock.
Our
existing stockholders may experience significant dilution from the sale of our common stock pursuant to certain financing agreements.
The
sale of our common stock pursuant to conversion of preferred stock or other convertible instruments, or pursuant to our equity line financing
will have a dilutive impact on our shareholders. As a result, the market price of our common stock could decline. In addition, the lower
our stock price, the greater the impact of dilution under these financing agreements. If our stock price decreases, then our existing
shareholders would experience greater dilution for any given dollar amount raised through such financing.
The
perceived risk of dilution may cause our stockholders to sell their shares, which may cause a decline in the price of our common stock.
Moreover, the perceived risk of dilution and the resulting downward pressure on our stock price could encourage investors to engage in
short sales of our common stock. By increasing the number of shares offered for sale, material amounts of short selling could further
contribute to progressive price declines in our common stock.
Our
stock is categorized as a penny stock. Trading of our stock may be restricted by the SEC’s penny stock regulations which may limit
a stockholder’s ability to buy and sell our stock.
Our
stock is categorized as a “penny stock”, as that term is defined in SEC Rule 3a51-1, which generally provides that “penny
stock”, is any equity security that has a market price (as defined) less than US$5.00 per share, subject to certain exceptions.
Our securities are covered by the penny stock rules, including Rule 15g-9, which impose additional sales practice requirements on broker-dealers
who sell to persons other than established customers and accredited investors. The penny stock rules require a broker-dealer, prior to
a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared
by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer
also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s
account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer
orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s
confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these
rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and
receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the
level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny
stock rules may affect the ability of broker-dealers to trade our securities and reduces the number of potential investors. We believe
that the penny stock rules discourage investor interest in and limit the marketability of our common stock.
According
to SEC Release No. 34-29093, the market for “penny stocks” has suffered in recent years from patterns of fraud and abuse.
Such patterns include: (1) control of the market for the security by one or a few broker-dealers that are often related to the promoter
or issuer; (2) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (3)
boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (4) excessive
and undisclosed bid-ask differential and markups by selling broker-dealers; and (5) the wholesale dumping of the same securities by promoters
and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices
and with consequent investor losses. The occurrence of these patterns or practices could increase the future volatility of our share
price.
FINRA
sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
In
addition to the “penny stock” rules described above, FINRA has adopted rules that require that in recommending an investment
to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to
recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain
information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations
of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least
some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock,
which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.
To
date, we have not paid any cash dividends and no cash dividends will be paid in the foreseeable future.
We
do not anticipate paying cash dividends on our common stock in the foreseeable future and we may not have sufficient funds legally available
to pay dividends. Even if the funds are legally available for distribution, we may nevertheless decide not to pay any dividends. We presently
intend to retain all earnings for our operations.
The
existence of indemnification rights to our directors, officers and employees may result in substantial expenditures by our Company and
may discourage lawsuits against our directors, officers and employees.
Our
bylaws contain indemnification provisions for our directors, officers and employees, and we have entered into indemnification agreements
with our officer and directors. The foregoing indemnification obligations could result in us incurring substantial expenditures to cover
the cost of settlement or damage awards against directors and officers, which we may be unable to recoup. These provisions and resultant
costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary duties and may similarly
discourage the filing of derivative litigation by our stockholders against our directors and officers even though such actions, if successful,
might otherwise benefit us and our stockholders.
If
we fail to develop or maintain an effective system of internal control over financial reporting, we may not be able to accurately report
our financial results or prevent financial fraud. As a result, current and potential stockholders could lose confidence in our financial
reporting.
We
are subject to the risk that sometime in the future, our independent registered public accounting firm could communicate to the board
of directors that we have deficiencies in our internal control structure that they consider to be “significant deficiencies.”
A “significant deficiency” is defined as a deficiency, or a combination of deficiencies, in internal control over financial
reporting such that there is more than a remote likelihood that a material misstatement of the entity’s financial statements will
not be prevented or detected by the entity’s internal control over financial reporting.
Effective
internal control over financial reporting is necessary for us to provide reliable financial reports and effectively prevent fraud. If
we cannot provide reliable financial reports or prevent fraud, we could be subject to regulatory action or other litigation and our operating
results could be harmed. As set forth in this report, as of March 31, 2023, Company management assessed the effectiveness of our internal
control over financial reporting (as defined in Rule 13a-15 and Rule 15d-15 under the Exchange Act) based on the criteria for effective
internal control over financial reporting established in Internal Control - Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission and SEC guidance on conducting such assessments. Management concluded that, during the fiscal
year ended March 31, 2023, the Company’s internal control over financial reporting was not effective. Management realized that
there were deficiencies in the design or operation of the Company’s internal control over financial reporting that adversely affected
it and that management considers to be material weaknesses. Such material weakness in our internal control over financial reporting
have not been remedied.
The
ineffectiveness of NaturalShrimp’s internal control over financial reporting was due to the following material weaknesses, which
are indicative of many small companies with small number of staff:
● | Inadequate
segregation of duties consistent with control objectives; |
● | Lack
of independent members of the board of directors (as of the balance sheet date) and the absence
of an audit committee to exercise oversight responsibility related to financial reporting
and internal control; |
● | Lack
of risk assessment procedures on internal controls to detect financial reporting risks in
a timely manner; and |
● | Lack
of documentation on policies and procedures that are critical to the accomplishment of financial
reporting objectives. |
Company
management continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated,
such that these controls are designed, implemented, and operating effectively.
The
remediation actions planned include:
● | Identify
gaps in our skills base and the expertise of its staff required to meet the financial reporting
requirements of a public company; |
● | Establish
an independent board of directors and an audit committee to provide oversight for remediation
efforts and ongoing guidance regarding accounting, financial reporting, overall risks, and
the internal control environment; |
● | Retain
additional accounting personnel with public company financial reporting, technical accounting,
Securities and Exchange Commission (the “SEC”) compliance, and strategic financial
advisory experience to achieve adequate segregation of duties; and |
● | Continue
to develop formal policies and procedures on accounting and internal control over financial
reporting and monitor the effectiveness of operations on existing controls and procedures. |
Company
management will continue to monitor and evaluate the relevance of its risk-based approach and the effectiveness of our internal control
over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements,
as necessary and as funds allow.
Our
intended business, operations, and accounting, including with respect to the Combined Company if the Business Combination is consummated,
are expected to be substantially more complex than they have been to date. It may be time consuming, difficult, and costly for us to
develop and implement the internal control and reporting procedures required by the Exchange Act. We may need to hire additional financial
reporting, internal control, and other finance personnel in order to develop and implement appropriate internal control and reporting
procedures. If we are unable to comply with the internal control over financial reporting requirements of the Exchange Act, then we may
not be able to obtain the required independent accountant certifications, which may preclude us from keeping our filings current with
the SEC.
Further,
a material weakness in the effectiveness of internal control over financial reporting could result in an increased chance of fraud and
the loss of customers, reduce our ability to obtain financing, and require additional expenditures to comply with these requirements,
each of which could have a material adverse effect on our business, results of operations, and financial condition. For additional information,
see Item 9A – Controls and Procedures.
If
we are unable to implement and maintain effective internal control over financial reporting, including as applicable standards governing
internal control are modified, supplemented, or amended from time to time, we may not be able to ensure that we can conclude on an ongoing
basis that we have effective internal control over financial reporting. Failure to achieve and maintain effective internal control over
financial reporting could cause us to face regulatory action and cause investors to lose confidence in our reported financial information,
either of which could adversely affect the value of our common stock.
General
Risk Factors Applicable to the Company
If
we lose our key management and technical personnel, our business may be adversely affected.
In
carrying out our operations, we rely upon a small group of key management and technical personnel including our Chief Executive Officer
and President, Chief Operating Officer and Chief Technology Officer, and Chief Financial Officer. We currently maintain key man insurance
for Tom Untermeyer as the Chief Operating Officer and Chief Technology Officer. An unexpected partial or total loss of the services of
any of our executive officers could be detrimental to our business.
Our
Chief Financial Officer and Treasurer does not devote his full time to the Company.
We
are highly dependent on the services of William Delgado, our Chief Financial Officer and Treasurer. Although Mr. Delgado allocates a
significant amount of time to the Company and is active in our management, he does not devote his full time and attention to us. In addition
to his positions with the Company, Mr. Delgado is also President, Chief Executive Officer, and Chief Financial Officer of Eco-Growth
Strategies, Inc., a nutraceutical company developing a range of CBD-based products, and Chief Executive Officer and Chairman of the Board
of Global Digital Solutions, Inc., an SEC reporting company that provides cyber arms technology and complementary security and technology
solutions. Mr. Delgado may also become involved in additional ventures from time to time.
We
face risks related to COVID-19 that could significantly disrupt our research and development, operations, sales, and financial results,
and other epidemics or outbreaks of infectious diseases may have a similar impact.
In
March 2020, the World Health Organization categorized COVID-19 as a pandemic. The spread of the outbreak caused significant disruptions
in the global economy, and the impact may continue to be significant. While the threat level has declined to a significant extent in
the United States and globally and COVID-19 is no longer considered a pandemic, and while our operations were not been materially and
negatively impacted by COVID-19 to date, our business could be adversely impacted by the effects of COVID-19 as well as government efforts
to control or combat it, particularly if there is a resurgence in infections, including as a result of the emergence of new variants
of the virus that causes COVID-19. In addition to global macroeconomic effects, the COVID-19 outbreak, and any other related adverse
public health developments could cause disruption to our operations and manufacturing activities. For example, if governments re-implement
restrictions in an attempt to combat any resurgence of COVID-19, we may experience disruptions to our business operations resulting from
quarantines, self-isolations, or other movement and restrictions on the ability of our employees to perform their jobs that may impact
our ability to develop and design our products and services in a timely manner or meet required milestones. Further, our third-party
equipment manufacturers, third-party raw material suppliers, and consultants have been and may continue to be disrupted by worker absenteeism,
quarantines, and restrictions on employees’ ability to work, office and factory closures, disruptions to ports and other shipping
infrastructure, border closures, or other travel or health-related restrictions, which could adversely affect our business and operations.
Other epidemics or outbreaks of infectious diseases could have similar impacts on us as well.
Worldwide
economic and social instability could adversely affect our revenue, financial condition, and results of operations.
The
health of the global economy, and the credit markets and the financial services industry in particular, as well as the stability of the
social fabric of our society, will affect our business and operating results. For example, the credit and financial markets may continue
to be adversely affected by the current conflict between Russia and Ukraine and measures taken in response thereto. If the credit markets
are not favorable, we may be unable to raise additional financing when needed or on favorable terms. Our customers may experience financial
difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability to purchase our products
or to pay for our products on a timely basis, if at all.
General
inflation, including rising energy prices, and interest rates and wages could have negative impacts on our business by increasing our
operating costs and our borrowing costs as well as decreasing the capital available for our customers to purchase our products. General
inflation in the United States, Europe and other geographies has risen to levels not experienced in recent decades. Additionally, inflation
and price volatility may cause our customers to reduce use of our products would harm our business operations and financial position.
We
need to raise additional funds and such funds may not be available on acceptable terms or at all.
We
may consider issuing additional debt or equity securities in the future to fund our business plan, for potential acquisitions or investments,
or for general corporate purposes. If we issue equity or convertible debt securities to raise additional funds, our existing stockholders
may experience dilution, and the new equity or debt securities may have rights, preferences, and privileges senior to those of our existing
stockholders. If we incur additional debt, it may increase our leverage relative to our earnings or to our equity capitalization, requiring
us to pay additional interest expenses. We may not be able to obtain financing on favorable terms, or at all, in which case, we may not
be able to develop or enhance our products, execute our business plan, take advantage of future opportunities, or respond to competitive
pressures.
As
the owner of real estate, we are subject to risks under environmental laws, the cost of compliance with which and any violation of which
could materially adversely affect us.
Our
operating expenses could be higher than anticipated due to the cost of complying with existing and future laws and regulations. Various
environmental laws may impose liability on the current or prior owner or operator of real property for removal or remediation of hazardous
or toxic substances. Current or prior owners or operators may also be liable for government fines and damages for injuries to persons,
natural resources, and adjacent property. These environmental laws often impose liability regardless of whether the owner or operator
knew of, or was responsible for, the presence or disposal of the hazardous or toxic substances. The cost of complying with environmental
laws could materially adversely affect our results of operations, and such costs could exceed the value of our applicable facility. In
addition, the presence of hazardous or toxic substances, or the failure to properly manage, dispose of, or remediate such substances,
may adversely affect our ability to use, sell, or rent our property or to borrow using our property as collateral which, in turn, could
reduce our revenue and our financing ability. We have not engaged independent environmental consultants to assess the likelihood of any
environmental contamination or liabilities and have not obtained a Phase I environmental assessment on our properties. Even if we did
obtain a Phase I environmental assessment report, however, such reports are limited in scope and might not reveal all existing material
environmental contamination.
Risk
Factors Related to the Pending Business Combination with Yotta Acquisition Corporation
We
may fail to realize all of the anticipated benefits of the Business Combination.
In
reaching its determination that the pending Business Combination with Yotta, as discussed above under “Item 1 – Business,”
the Merger Agreement and the related agreements, and the other transactions contemplated by the Merger Agreement and the related agreements,
were advisable and in the best interests of the Company and its stockholders, and in adopting and approving such matters, our board of
directors considered, among other things: (i) that the Combined Company’s common stock would be listed on The Nasdaq Stock Market
LLC (“Nasdaq”); (ii) the implied enterprise value of the Business Combination of approximately $175 million for the Company,
providing its securityholders with the opportunity to go forward with ownership in a company with a larger market capitalization; and
(iii) the board’s expectation that the Business Combination would be a more time- and cost-effective means to access capital, repay
a portion of our existing indebtedness, and reduce leverage than other options that the Company had considered. The success of the Business
Combination, however, will depend, in part, on a number of factors, including the challenges and risks currently faced by the Company
as discussed in this report, some of which our outside of our control, and the reaction of current and potential investors to the Business
Combination. As a result, the anticipated benefits of the Business Combination may not be realized fully or at all or may take longer
to realize than expected.
Stockholder
litigation and regulatory inquiries and investigations are expensive and could harm our operating results and could divert management’s
attention.
In
the past, securities class action litigation and/or stockholder derivative litigation and inquiries or investigations by regulatory authorities
have often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction,
such as the Business Combination. Any stockholder litigation and/or regulatory investigations against the Company, whether or not resolved
in our favor, could result in substantial costs and divert management’s attention from other business concerns, which could adversely
affect our business and cash resources and the ultimate value that our stockholders receive as a result of the Business Combination.
The
market price and trading volume of the Combined Company’s common stock may be volatile and could decline significantly following
the Business Combination.
The
stock markets, including Nasdaq on which the shares of the Combined Company’s common stock to be issued in the Business Combination
are expected to be traded, have from time-to-time experienced significant price and volume fluctuations. Even if an active, liquid, and
orderly trading market develops and is sustained for the Combined Company’s common stock following the Business Combination, the
market prices of shares of the Combined Company’s common stock may be volatile and could decline significantly. In addition, the
trading volumes in shares of the Combined Company’s common stock may fluctuate and cause significant price variations to occur.
If the market prices of the Combined Company’s common stock decline significantly, holders of the Combined Company’s common
stock, including our stockholders who receive shares of the Combined Company’s common stock in the Business Combination, may be
unable to resell their shares of the Combined Company’s common stock at or above the market price of the shares of the Combined
Company’s common stock as of the date immediately following the consummation of the Business Combination. There can be no assurance
that the market prices of shares of the Combined Company’s common stock will not fluctuate widely or decline significantly in the
future in response to a number of factors, including, among others, the following:
● |
the
realization of any of the risk factors discussed in this report; |
● |
actual
or anticipated differences in our estimates, or in the estimates of analysts, for the Combined Company’s revenues, results
of operations, cash flows, level of indebtedness, liquidity, or financial condition; |
● |
actual
or anticipated variations in the Combined Company’s quarterly operating results; |
● |
announcements
by the Combined Company or its competitors of significant business developments; |
● |
the
Combined Company’s ability to obtain adequate working capital financing; |
● |
loss
of any strategic relationships; |
● |
actions
by the Combined Company’s stockholders (including transactions in shares of the Combined Company’s common stock); |
● |
changes
in applicable laws or regulations, court rulings, enforcement, and legal actions; |
● |
sale
of shares of the Combined Company’s common stock or other securities in the future; |
● |
changes
in market valuations of similar companies and general market conditions in our industry; |
● |
publication
(or lack of publication) of research reports about the Combined Company; |
● |
the
trading volume of shares of the Combined Company’s common stock; |
● |
additions
or departures of key management personnel; |
● |
speculation
in the press or investment community; |
● |
continuing
increases in market interest rates, which may increase the Combined Company’s cost of capital; |
● |
changes
in our industry; |
● |
actual,
potential, or perceived control, accounting, or reporting problems; |
● |
changes
in accounting principles, policies, and guidelines; |
● |
other
events or factors, including but not limited to those resulting from infectious diseases, health epidemics and pandemics (including
but not limited to the recent COVID-19 pandemic) natural disasters, war, acts of terrorism, or responses to these events; |
● |
our
ability to execute the Combined Company’s business plan; and |
● |
general
economic and market conditions. |
In
addition, the securities markets have periodically experienced extreme price and volume fluctuations that are unrelated to the operating
performance of particular companies. These market fluctuations may also materially and adversely affect the market price of the Combined
Company’s common stock. In the past, following periods of volatility in the market price of a company’s securities, securities
class action litigation has often been instituted against that company. If the Combined Company were involved in any similar litigation it could incur substantial costs and its management’s attention and resources could be diverted from running the business and implementing
its business plan.
We
are subject to business uncertainties while the Business Combination is pending.
Uncertainty
about the effect of the Business Combination on employees, customers, suppliers, and vendors may have an adverse effect on our business,
financial condition, and results of operations. These uncertainties may impair our ability to attract, retain, and motivate key personnel
pending the consummation of the Business Combination. Additionally, these uncertainties could cause customers, suppliers, vendors, and
others who deal with us to seek to change existing business relationships with us or fail to extend an existing relationship. In addition,
competitors may target our key personnel or other employees by highlighting potential uncertainties relating to or that may result from
the Business Combination.
Further,
the pursuit of the Business Combination may place a burden on Company management and resources. Any significant diversion of management
attention away from ongoing business concerns and any difficulties encountered in the transition process could have a material adverse
effect on our business, financial condition, and results of operations both before and after consummation of the Business Combination.
If
the Business Combination is not completed, we will have incurred substantial expenses without realizing the expected benefits.
We
have incurred substantial expenses in connection with the execution of the Merger Agreement and the Business Combination. The completion
of the Business Combination depends on the satisfaction of specified conditions, including the receipt of the requisite approval of Yotta’s
stockholders. There is no guarantee that these conditions will be met. If the Business Combination is not completed, these expenses could
have a material adverse impact on our financial condition because we would not have realized the expected benefits for which these expenses
were incurred.
Failure
to complete the Business Combination could negatively impact our stock price, business and financial results.
If
the Business Combination is not completed, our business be adversely affected and we will be subject to several risks, including the
following:
● | We
will be required to pay certain costs relating to the Business Combination, whether or not
the Business Combination is completed, such as legal and accounting fees; and |
● | Matters
relating to the Business Combination may require substantial commitments of management time
and resources that could otherwise have been devoted to other opportunities that may have
been beneficial to the Company as an independent company. |
In
addition, if the Business Combination is not completed, we may experience negative reactions from the financial markets and from our
stockholders, customers, and employees. We also could be subject to litigation related to any failure to complete the Business Combination
or to proceedings commenced against us to perform our obligations under the Merger Agreement.
If
the Business Combination is not completed, we cannot assure our stockholders that the risks described above will not materialize and
will not materially affect our business, financial results, and stock price.
The
Combined Company will issue shares of its common stock as consideration in the Business Combination and may issue additional shares of
its common stock or other equity or convertible debt securities without approval of the holders of the Combined Company’s common
stock, which would dilute then-existing ownership interests and may depress the market price of the Combined Company’s common stock.
The
Combined Company may continue to require capital investment to support its business and may issue additional shares of its common stock
or other equity or convertible debt securities of equal or senior rank in the future without approval of its stockholders in certain
of circumstances.
The
Combined Company’s issuance of additional shares of its common stock or other equity or convertible debt securities would have
the following effects: (i) the Combined Company’s existing stockholders’ proportionate ownership interest in the Combined
Company would decrease; (ii) the amount of cash available per share, including for payment of dividends in the future, may decrease;
(iii) the relative voting power of each previously outstanding shares of the Combined Company’s common stock may be diminished;
and (iv) the market price of the Combined Company’s common stock may decline.
There
will be material differences between the current rights of holders of the Company’s common stock and the rights former Company
stockholders will have as a holder of the Combined Company’s common stock, some of which may adversely affect such stockholders.
Upon
completion of the Business Combination, the Company’s stockholders will no longer be stockholders of the Company but will be stockholders
of the Combined Company. There will be material differences between the current rights of the Company’s stockholders and the rights
that current Company stockholders will have as a holder of shares of the Combined Company’s common stock, some of which may adversely
affect our current stockholders.
If
securities or industry analysts do not publish research, publish inaccurate or unfavorable research, or cease publishing research about
the Combined Company, its share price and trading volume could decline significantly.
The
trading market for the Combined Company’s common stock will depend, in part, on the research and reports that securities or industry
analysts publish about the Combined Company or its business. The Combined Company may be unable to sustain coverage by well-regarded
securities and industry analysts. If either no or only a limited number of securities or industry analysts maintain coverage of the Combined
Company, or if these securities or industry analysts are not widely respected within the general investment community, the demand for
the Combined Company’s common stock could decrease, which might cause its share price and trading volume to decline significantly.
In the event that the Combined Company obtains securities or industry analyst coverage, or if one or more of the analysts who cover the
Combined Company downgrade their assessment of the Combined Company or publish inaccurate or unfavorable research about the Combined
Company’s business, the market price and liquidity for the Combined Company’s common stock could be negatively impacted.
Future
resales of shares of the Combined Company’s common stock issued to Company stockholders and other significant stockholders may
cause the market price of the Combined Company’s common stock to drop significantly, even if the Combined Company’s business
is doing well.
Pursuant
to lock-up agreements executed concurrently with the Merger Agreement, certain of the Combined Company’s stockholders will be restricted,
subject to certain exceptions, from selling any of the Combined Company’s common stock that they receive in or hold at the effective
time of the Business Combination, which restrictions will expire and therefore additional Combined Company’s common stock will
be eligible for resale, six months after the effective time of the Business Combination.
Subject
to the lock-up agreements, the Company stockholders that are a party thereto (which are the Company’s three executive officers
and directors) may sell the Combined Company’s common stock pursuant to Rule 144 under the Securities Act (“Rule 144”),
if available. In these cases, the resales must meet the criteria and conform to the requirements of that rule, including, because Yotta
is currently a shell company, waiting until one year after the Combined Company’s filing with the SEC of Form 10-type information
reflecting the Business Combination.
Upon
expiration of the lock-up periods provided for in such agreements, and upon effectiveness of the registration statement that the Combined
Company is obligated to file to register the resale of such shares with the SEC or upon satisfaction of the requirements of Rule 144,
certain former Yotta stockholders and certain other significant stockholders of the Combined Company may sell large amounts of the Combined
Company’s common stock in the open market or in privately-negotiated transactions, which could have the effect of increasing the
volatility in the Combined Company’s share price or putting significant downward pressure on the price of the Combined Company’s
common stock.
We
do not expect that the Combined Company will pay dividends in the foreseeable future after the Business Combination.
We
expect that the Combined Company will retain most, if not all, of its available funds and any future earnings after the Business Combination
to fund its operations and the development and growth of its business. As a result, we do not expect that the Combined Company will pay
any cash dividends on the Combined Company’s common stock in the foreseeable future.
Following
completion of the Business Combination, the Combined Company’s board of directors will have complete discretion as to whether to
distribute dividends. Even if the board of directors decides to declare and pay dividends, the timing, amount, and form of such dividends,
if any, will depend on the future results of operations and cash flow, capital requirements, and surplus, the amount of distributions,
if any, received by the Combined Company from its subsidiaries, the Combined Company’s financial condition, contractual restrictions,
and other factors deemed relevant by the board of directors. There is no guarantee that the shares of the Combined Company’s common
stock will appreciate in value after the Business Combination or that the trading price of the shares will not decline. Holders of the
Combined Company’s common stock should not rely on an investment in shares of the Combined Company’s common stock as a source
for any future dividend income.
The
existence of indemnification rights to the Combined Company’s directors, officers, and employees may result in substantial expenditures
by the Combined Company and may discourage lawsuits against its directors, officers, and employees.
The
intended bylaws of the Combined Company contain indemnification provisions for its directors, officers, and employees. Such indemnification
obligations could result in the Combined Company incurring substantial expenditures to cover the cost of settlement or damage awards
against its directors, executive officers, and employees, which it may be unable to recoup. These provisions and resultant costs may
also discourage the Combined Company from bringing a lawsuit against its directors and executive officers for breaches of their fiduciary
duties and may similarly discourage the filing of derivative litigation by its stockholders against its directors and officers even though
such actions, if successful, might otherwise benefit the Combined Company and its stockholders.
The
Combined Company will be required to meet the initial listing requirements to be listed on Nasdaq. However, the Combined Company may
be unable to maintain the listing of its securities in the future.
If
the Combined Company fails to meet the continued listing requirements and Nasdaq delists its securities, it could face significant material
adverse consequences, including:
● |
a
limited availability of market quotations for its securities; |
● |
a
limited amount of news and analyst coverage for the Combined Company; and |
● |
a
decreased ability to issue additional securities or obtain additional financing in the future. |
ITEM
1B. UNRESOLVED STAFF COMMENTS
Not
Applicable.
ITEM
2. PROPERTIES
Our
principal offices are located at 5501 LBJ Freeway, Suite 450, Dallas, Texas 75240, where we pay $7,000 per month under an operating lease
that expires on December 31, 2023, provided, however, that based on rent abatement provisions related to early termination of the lease
agreement, which was originally scheduled to terminate on October 31, 2025, and pre-paid rent, no rental payments will be due for this
office space during calendar year 2023.
We
intend to rebuild our 8,000 square foot water treatment plant and maintain, own and operate a 40,000 square foot production facility
on 37 acres at 833 County Road 583, La Coste, Texas.
We
own 344,000 square feet of production facilities consisting of:
|
● |
270,000
square feet on 13 acres at 401 Des Moines Street, Webster City, Iowa; |
|
● |
50,000
square feet on 20 acres at 2567 190th Street, Blairsburg, Iowa; and |
|
● |
24,000
square feet on 20 acres at 12282 200th Street, Radcliffe, Iowa. |
Our
registered agent is Business Filings Incorporated, located at 701 S. Carson Street, Suite 200, Carson City, Nevada 89701.
ITEM
3. LEGAL PROCEEDINGS
From time to time, we may become involved in actions, claims, suits, and other legal proceedings arising in the normal
course of our business. Neither NaturalShrimp nor its subsidiaries are currently a party, nor is any of our property subject, to any actions,
claims, suits, or other legal proceedings the outcome of which, in management’s opinion, would, if determined adversely to us, individually
or in the aggregate have a material adverse effect on our business, financial condition, or results of operations.
ITEM
4. MINE SAFETY DISCLOSURES
Not
applicable.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE FISCAL YEARS ENDED MARCH 31, 2023 AND 2022
NOTE
1 – NATURE OF THE ORGANIZATION AND BUSINESS
Nature
of the Business
NaturalShrimp
Incorporated (“NaturalShrimp” or the “Company”), a Nevada corporation, is a biotechnology company and has developed
a proprietary technology that allows it to grow Pacific White shrimp (Litopenaeus vannamei, formerly Penaeus vannamei) in an ecologically
controlled, high-density, low-cost environment, and in fully contained and independent production facilities. The Company’s system
uses technology which allows it to produce a naturally-grown shrimp “crop” weekly and accomplishes this without the use of
antibiotics or toxic chemicals. The Company has developed several proprietary technology assets, including a knowledge base that allows
it to produce commercial quantities of shrimp in a closed system with a computer monitoring system that automates, monitors and maintains
proper levels of oxygen, salinity and temperature for optimal shrimp production. The Company’s production facilities are located
in La Coste, Texas and Webster City, Iowa.
The
Company has three wholly-owned subsidiaries including NaturalShrimp USA Corporation, NaturalShrimp Global, Inc. and Natural Aquatic Systems,
Inc. (“NAS”), and owns 51% of NaturalShrimp/Hydrenesis LLC, a Texas limited liability company.
Going
Concern
The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (“GAAP”), assuming the Company will continue as a going concern, which contemplates the realization
of assets and satisfaction of liabilities in the normal course of business. For the year ended March 31, 2023, the Company had a net
loss available for common stockholders of approximately $17,497,000. As of March 31, 2023, the Company had an accumulated deficit of
approximately $167,533,000 and a working capital deficit of approximately $9,339,000. These factors raise substantial doubt about the
Company’s ability to continue as a going concern, within one year from the issuance date of this filing. The Company’s ability
to continue as a going concern is dependent on its ability to raise the required additional capital or debt financing to meet short and
long-term operating requirements. During the year ended March 31, 2023, the Company received net cash proceeds of approximately $3,076,000
from the sale of common shares (See Note 12), and $1,715,000 proceeds from the issuance of promissory notes.
The
Company is currently in the process of obtaining the requisite approvals to close a business combination with a special purpose acquisition
corporation (“SPAC”) (See Note 17). Upon the closing of such business combination, the Company is expecting to obtain funding
for their operations through the cash held by the SPAC’s Trust Account, in addition to any backstop financing that the SPAC may
need to pursue in the event that the Trust Account does not have sufficient funds available after redemptions. The Company can provide
no assurance that the transactions with the SPAC will be successful or that, even if the business combination is successful, that there
will be sufficient funds available from such transaction. The Company may also encounter business endeavors that require significant
cash commitments or unanticipated problems or expenses that could result in a requirement for additional cash. If the Company raises
additional funds through the issuance of equity, the percentage ownership of its current shareholders could be reduced, and such securities
might have rights, preferences or privileges senior to its common stock. Additional financing may not be available upon acceptable terms,
or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage
of prospective business endeavors or opportunities, which could significantly and materially restrict its operations. The Company continues
to pursue external financing alternatives to improve its working capital position. If the Company is unable to obtain the necessary capital,
the Company may be unable to develop its facilities and enter into production.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Consolidation
The
consolidated financial statements include the accounts of NaturalShrimp Incorporated and its wholly-owned subsidiaries, NaturalShrimp
USA Corporation, NaturalShrimp Global and NAS. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use
of Estimates
Preparing
financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
Basic
and Diluted Earnings/Loss per Common Share
Basic
and diluted earnings or loss per share (“EPS”) amounts in the consolidated financial statements are computed in accordance
with ASC 260 – 10 “Earnings per Share”, which establishes the requirements for presenting EPS. Basic EPS is based on
the weighted average number of shares of common stock outstanding. Diluted EPS is based on the weighted average number of shares of common
stock outstanding and dilutive common stock equivalents. Basic EPS is computed by dividing net income or loss available to common stockholders
(numerator) by the weighted average number of shares of common stock outstanding (denominator) during the period. For the year ended
March 31, 2023, the Company had 5,000,000 Series A Convertible Preferred Stock which would be converted at the holder’s option
into approximately 803,124,000 underlying common shares, 1,500 of Series E Redeemable Convertible Preferred shares whose approximately
5,143,000 underlying shares are convertible at the investors’ option at a fixed conversion price of $0.35 and 170 shares of Series
E Redeemable Convertible Preferred shares whose approximately 3,192,000 underlying shares are convertible at the investors’ option
at conversion price of 90% of the average of the two lowest market prices over the last 10 days, 750,000 shares of Series F Preferred
Stock which would be converted at the holders’ option into approximately 192,750,000 underlying common shares, and 18,573,116 warrants
outstanding which were not included in the calculation of diluted EPS as their effect would be anti-dilutive. For the year ended March
31, 2022, the Company had 5,000,000 Series A Convertible Preferred Stock which would be converted at the holder’s option into approximately
674,832,000 underlying common shares, 2,840 of Series E Redeemable Convertible Preferred shares whose approximately 9,737,000 underlying
shares are convertible at the investors’ option at a fixed conversion price of $0.35, 750,000 shares of Series F Preferred Stock
which would be converted at the holders’ option into approximately 162,080,000 underlying common shares, and approximately $18,768,000
in a convertible debenture whose approximately 98,779,000 underlying shares are convertible at the holders’ option at conversion
price of 90% of the average of the two lowest market prices over the last 10 days and 18,573,116 warrants outstanding which were not
included in the calculation of diluted EPS as their effect would be anti-dilutive.
Fair
Value Measurements
ASC
Topic 820, “Fair Value Measurement”, requires that certain financial instruments be recognized at their fair values
at our balance sheet dates. However, other financial instruments, such as debt obligations, are not required to be recognized at their
fair values, but GAAP provides an option to elect fair value accounting for these instruments. GAAP requires the disclosure of the fair
values of all financial instruments, regardless of whether they are recognized at their fair values or carrying amounts in our balance
sheets. For financial instruments recognized at fair value, GAAP requires the disclosure of their fair values by type of instrument,
along with other information, including changes in the fair values of certain financial instruments recognized in income or other comprehensive
income. For financial instruments not recognized at fair value, the disclosure of their fair values is provided below under Financial
Instruments.
Nonfinancial
assets, such as property, plant and equipment, and nonfinancial liabilities are recognized at their carrying amounts in the Company’s
balance sheets. GAAP does not permit nonfinancial assets and liabilities to be remeasured at their fair values. However, GAAP requires
the remeasurement of such assets and liabilities to their fair values upon the occurrence of certain events, such as the impairment of
property, plant and equipment. In addition, if such an event occurs, GAAP requires the disclosure of the fair value of the asset or liability
along with other information, including the gain or loss recognized in income in the period the remeasurement occurred.
The
Company did not have any Level 1 or Level 2 assets and liabilities as of March 31, 2023 and March 31, 2022.
The
derivative and warrant liabilities, and fair value option on Restructured notes are Level 3 fair value measurements.
The
following is a summary of activity of Level 3 liabilities during the years ended March 31, 2023 and 2022:
SCHEDULE OF DERIVATIVE AND WARRANT AND PROMISSORY NOTE AT FAIR VALUE
Derivatives
| |
2023 | | |
2022 | |
Derivative liability balance at beginning of year | |
$ | 13,101,000 | | |
$ | - | |
Removal of conversion feature upon restructuring of convertible note | |
| (12,290,000 | ) | |
| - | |
Additions to derivatives | |
| - | | |
| 12,985,000 | |
Change in fair value | |
| (811,000 | ) | |
| 116,000 | |
Balance at end of year | |
$ | - | | |
$ | 13,101,000 | |
The
derivative liability does not exist as of March 31, 2023, as the convertible note removed the conversion feature upon its restructuring
on November 4, 2022, and there is no longer an embedded derivative to be bifurcated (Note 9). Upon restructuring of the convertible note,
the fair value of the derivative liability at that date and removal of the conversion feature was estimated using a bi-nomial model with
the following weighted-average inputs: the price of the Company’s common stock of $0.16; a risk-free interest rate of 3.73% and
expected volatility of the Company’s common stock of 117.77%.
At
March 31, 2022, the fair value of the derivative liabilities of convertible notes was estimated using a bi-nomial model with the following
weighted-average inputs: the price of the Company’s common stock of $0.225; a risk-free interest rate of 2.28% and expected volatility
of the Company’s common stock of 109.47%, and the remaining term of 1.75 years.
SCHEDULE
OF DERIVATIVE AND WARRANT AND PROMISSORY NOTE AT FAIR VALUE
Warrant
liability
| |
2023 | | |
2022 | |
Warrant liability balance at beginning of year | |
$ | 3,923,000 | | |
$ | - | |
Additions to warrant liability | |
| - | | |
| 5,910,000 | |
Reclass to equity upon cancellation or exercise | |
| - | | |
| - | |
Change in fair value | |
| (3,568,000 | ) | |
| (1,987,000 | ) |
Balance at end of year | |
$ | 355,000 | | |
$ | 3,923,000 | |
At March 31, 2023, the fair value of the warrant liability was estimated using a Black Sholes model with the following
weighted-average inputs: the price of the Company’s common stock of $0.05; a risk-free interest rate of 3.81% and expected volatility
of the Company’s common stock ranging from 113.6% to 121.0% and the remaining terms of each warrant issuance.
At
March 31, 2022, the fair value of the warrant liability was estimated using a Black Sholes model with the following weighted-average
inputs: the price of the Company’s common stock of $0.225; a risk-free interest rate of 2.42% and expected volatility of the Company’s
common stock ranging from 185.9% to 205.9% and the remaining terms of each warrant issuance.
SCHEDULE
OF DERIVATIVE AND WARRANT AND PROMISSORY NOTE AT FAIR VALUE
Promissory
Note
| |
2023 | | |
2022 | |
Promissory Notes fair value at beginning of year | |
$ | - | | |
$ | - | |
Fair value of Promissory Notes upon Restructuring Agreement | |
| 20,847,867 | | |
| - | |
Change in fair value | |
| 2,842,133 | | |
| - | |
Promissory Note fair value at end of year | |
$ | 23,690,000 | | |
$ | - | |
On
November 4, 2022, when the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note for two
of their outstanding debentures (Note 6 and Note 7), which were accounted for as debt extinguishment, the Company elected to recognize
the new debt under ASC 825 fair value option. The fair value was based on the maturity dates, the interest of 12%, the 15% exit fee,
the 2% appreciation fee for an estimated period, and a 40% present value factor.
Financial
Instruments
The
Company’s financial instruments include cash and cash equivalents, receivables, payables, and debt and are accounted for under
the provisions of ASC Topic 825, “Financial Instruments”. The carrying amount of these financial instruments, with
the exception of discounted debt, as reflected in the consolidated balance sheets approximates fair value.
Cash
and Cash Equivalents
For
the purpose of the consolidated statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity
of three months or less to be cash equivalents. There were no cash equivalents as of March 31, 2023 and March 31, 2022.
Concentration
of Credit Risk
The
Company maintains cash balances at two financial institutions. Accounts at this institution are insured by the Federal Deposit Insurance
Corporation (FDIC) up to $250,000. As of March 31, 2023, the Company’s cash balance did not exceed FDIC coverage. As of March 31,
2022 the Company’s cash balance exceeded FDIC coverage. The Company has not experienced any losses in such accounts and periodically
evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
Fixed
Assets
Equipment
is carried at historical value or cost and is depreciated using the straight-line method over the estimated useful lives of the related
assets. Estimated useful lives are as follows:
SCHEDULE
OF ESTIMATED USEFUL LIVES
Buildings | |
| 39 years | |
Machinery and Equipment | |
| 7 – 10 years | |
Vehicles | |
| 10 years | |
Furniture and Fixtures | |
| 3 – 10 years | |
Maintenance
and repairs are charged to expense as incurred. At the time of retirement or other disposition of equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.
Income
Taxes
Deferred
income tax assets and liabilities are computed for differences between the financial statement and tax basis of assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which
the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during
the period in deferred tax assets and liabilities.
In
addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in
the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely
than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be
performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.
Stock-Based
Compensation
The
Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718. “Stock-based Compensation
to Employees” is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite
employee service period. The Company estimates the fair value of stock-based payments using the Black-Scholes option-pricing model for
common stock options and warrants and the closing price of the Company’s common stock for common share issuances. Once the stock
is issued the appropriate expense account is charged.
Intangible
Assets
The
Company has intangible assets, which were acquired in a patent acquisition, and license rights agreements. The Company’s patents
represent definite lived intangible assets and will be amortized over the twenty-year duration of the patent, unless at some point the
useful life is determined to be less than the protected life of the patent. The Company’s license rights will be amortized on a
straight-line basis over the expected term of the agreements of ten years. The Company periodically evaluates the remaining useful lives
of its finite-lived intangible assets to determine whether events and circumstances warrant a revision to the remaining period of amortization.
As of March 31, 2023 and 2022, the Company believes the carrying value of the intangible assets are still recoverable, and there is no
impairment to be recognized.
Impairment
of Long-lived Assets
The
Company will periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances warrant
such a review and at least annually. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted
cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a loss is recognized based on
the amount by which the carrying value exceeds the fair value of the long-lived asset. Fair value is determined primarily using the anticipated
cash flows discounted at a rate commensurate with the risk involved. Losses on long-lived assets to be disposed of are determined in
a similar manner, except that fair values are reduced for the cost to dispose.
Commitments
and Contingencies
Certain
conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which
will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess
such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related
to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s
legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount
of relief sought or expected to be sought therein.
If
the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability
can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment
indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated,
then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would
be disclosed.
Loss
contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee
would be disclosed.
Revenue
Recognition
The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, as
such, the Company records revenue when its customers obtain control of the promised goods or services in an amount that reflects the
consideration which the Company expects to receive in exchange for those goods or services. The Company will sell primarily to food service
distributors, as well as to wholesalers, retail establishments and seafood distributors.
To
determine revenue recognition for the arrangements that the Company determines are within the scope of Topic 606, the Company performs
the following five steps: (1) identify the contract(s) with a customer by receipt of purchase orders and confirmations sent by the Company
which includes a required line of credit approval process, (2) identify the performance obligations in the contract which includes shipment
of goods to the customer FOB shipping point or destination, (3) determine the transaction price which initiates with the purchase order
received from the customer and confirmation sent by the Company and will include discounts and allowances by customer if any, (4) allocate
the transaction price to the performance obligations in the contract which is the shipment of the goods to the customer and transaction
price determined in step 3 above and (5) recognize revenue when (or as) the entity satisfies a performance obligation which is when the
Company transfers control of the goods to the customers by shipment or delivery of the products.
In
the future, if the Company has customers with long-term contracts for multiple shipments of live shrimp, the Company will elect the right-to-invoice
practical expedient and any variable consideration estimate will be excluded from the transaction price and the revenue will be recognized
directly when the goods are delivered.
Recently
Issued Accounting Standards
In
August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and
Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s
Own Equity” (“ASU 2020-06”), which simplifies the accounting for certain financial instruments with characteristics
of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by
removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial
conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises
the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both
indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity
classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share
(EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes
of calculating diluted EPS when an instrument may be settled in cash or shares. For SEC filers, excluding smaller reporting companies,
ASU 2020-06 is effective for fiscal years beginning after December 15, 2021 including interim periods within those fiscal years. Early
adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. For all other entities, ASU 2020-06 is effective
for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Entities should adopt the guidance
as of the beginning of the fiscal year of adoption and cannot adopt the guidance in an interim reporting period. The Company does not
expect that ASU 2020-06 will have a material impact on its consolidated financial statements and related disclosures.
In
June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses
on Financial Instruments,” which requires the Company to measure and recognize expected credit losses for financial assets held
and not accounted for at fair value through net income. In November 2018, April 2019 and May 2019, the FASB issued ASU No. 2018-19, “Codification
Improvements to Topic 326, Financial Instruments — Credit Losses,” “ASU No. 2019-04, Codification Improvements to Topic
326, Financial Instruments — Credit Losses,” “Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,”
and “ASU No. 2019-05, Financial Instruments — Credit Losses (Topic 326): Targeted Transition Relief,” which provided
additional implementation guidance on the previously issued ASU. The ASU is effective for fiscal years beginning after Dec. 15, 2019
for public business entities that meet the definition of an SEC filer, excluding entities eligible to be SRCs as defined by the SEC.
All other entities, ASU No. 2016-13 is effective for fiscal years beginning after December 15, 2022. The adoption of this guidance is
not expected to have a material impact on the Company’s consolidated financial statements.
As
of March 31, 2023, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these
pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting
pronouncements has had or will have a material impact on the Company’s consolidated financial statements.
Management’s
Evaluation of Subsequent Events
The
Company evaluates events that have occurred after the balance sheet date of March 31, 2023, through the date which the consolidated financial
statements were issued. Based upon the review, other than described in Note 18 – Subsequent Events, the Company did not identify
any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.
NOTE
3 – RESTATEMENTOF PREVIOUSLY ISSUED FINANCIAL STATEMENT
As
a result of the findings based on the SEC Staff comments and the Company’s ongoing reviews, the Company, in consultation with the
Board of Directors, determined that the previously issued Consolidated Statement of Cash Flow presented in the Form 10-K filed on June
29, 2022, for the year ended March 31, 2022 had a clerical error in the cash paid for the License Agreement and we would make the necessary
accounting corrections and restate such financial statement.
The
errors included in addition to the incorrect amount shown as the cash paid through the end of the year for the License Agreement, the
presentations did not follow the guidance under ASC 230-10 as to the future payments to be presented as financing activity.
Following
is a comprehensive list of all revised adjustments made during the Restatement Process:
SCHEDULE
OF PREVIOUSLY ISSUED FINANCIAL STATEMENT
| |
As Previously Reported | | |
Adjustments | | |
As Revised | |
Cash Flow Statement for the year ended March 31, 2022 | |
| | | |
| | | |
| | |
Prepaid expenses and other current assets | |
$ | (1,506,207 | ) | |
$ | 650,000 | | |
$ | (856,207 | ) |
Accounts payable | |
| (2,657,052 | ) | |
| 3,000,000 | | |
| 342,948 | |
CASH USED IN OPERATING ACTIVITIES | |
| (12,575,244 | ) | |
| 3,650,000 | | |
| (8,925,244 | ) |
Payments due on License Agreement | |
| — | | |
| (3,000,000 | ) | |
| (1,250,000 | ) |
| |
| | | |
| 2,400,000 | | |
| | |
| |
| | | |
| (650,000 | ) | |
| | |
Payments made on License Agreement | |
| — | | |
| (2,400,000 | ) | |
| (2,400,000 | ) |
CASH PROVIDED BY FINANCING ACTIVITIES | |
| 22,585,954 | | |
| (3,650,000 | ) | |
| 18,935,954 | |
NOTE
4 – FIXED ASSETS
A
summary of the fixed assets as of March 31, 2023 and March 31, 2022 is as follows:
SCHEDULE
OF FIXED ASSETS
| |
| | |
| |
| |
March
31, 2023 | | |
March
31, 2022 | |
Land | |
$ | 324,293 | | |
$ | 324,293 | |
Buildings | |
| 5,495,150 | | |
| 5,611,723 | |
Machinery and equipment | |
| 12,293,112 | | |
| 10,524,343 | |
Autos and trucks | |
| 307,227 | | |
| 247,356 | |
Fixed assets,Gross | |
| 18,419,782 | | |
| 16,707,715 | |
Accumulated depreciation | |
| (3,376,067 | ) | |
| (1,909,612 | ) |
Fixed assets, net | |
$ | 15,043,715 | | |
$ | 14,798,103 | |
The
consolidated statements of operations reflect depreciation expense of approximately $1,795,000 and $1,307,000 for the years ended March
31, 2023 and 2022, respectively.
NOTE
5 – PATENT ACQUISITION
On
May 19, 2021, the Company entered into a Patents Purchase Agreement (the “Patents Agreement”) with F&T. The Company and
F&T had previously jointly developed and patented a water treatment technology used or useful in growing aquatic species in re-circulating
and enclosed environments (the “Patent”) with each party owning a fifty percent (50%) interest. Upon the closing of the Patents
Agreement, the Company would purchase F&T’s interest in the Patent, F&T’s 100% interest in a second patent associated
with the first Patent issued to F&T in March 2018, and all other intellectual property rights owned by F&T for a purchase price
of $2,000,000 in cash and issue 9,900,990 shares of the Company’s common stock with a market value of $0.505 per share for a total
fair value of $5,000,000, for a total acquisition price of $7,000,000. The Company paid the cash purchase price on May 20, 2021 and the
closing of the Patents Agreement took place on May 25, 2021.
In
accordance with ASC 805-10-55-5A, as substantially all the assets acquired are concentrated in a single identifiable asset, the patents,
the acquisition has been determined to not be considered a business combination but an asset acquisition. The consideration is allocated
to the two patents, which were both approved in December, 2018, and will be amortized through the earliest of their useful life or December,
2038. Amortization over the next five years is expected to be $390,000 per year, for a total of $1,950,000. Amortization expense was
$390,000 and $341,500 for the years ended March 31, 2023 and 2022.
NOTE
6 – LICENSE AGREEMENTS
On
August 25, 2021, the Company, through their 100% owned subsidiary NAS, entered into an Equipment Rights Agreements with Hydrenesis-Delta
Systems, LLC (“Hydrenesis-Delta”) and a Technology Rights Agreement, in a sub-license agreement with Hydrenesis Aquaculture
LLC (“Hydrenesis-Aqua”), The Equipment Rights involve specialized and proprietary equipment used to produce and control,
dose, and infuse Hydrogas® and RLS® into both water and other chemical species, while the Technology sublicense pertains to the
rights to Hydrogas® and RLS®. Both Rights agreements are for a 10-year term, which shall automatically renew for ten-year successive
terms. The term can be terminated by written notice by mutual consent, or by either party upon a breach of contract, insolvency or filing
of bankruptcy. The agreements accord the exclusive rights to purchase or distribute the technology, or buy or rent the equipment, in
the Industry Sector, which is the primary business and revenue stream generated from indoor aquaculture farming of any species in the
Territory, defined as anywhere in the world except for the countries in the Gulf Corporation Council.
The
consideration for the Equipment Rights consists of the sum of $2,500,000, with $500,000 in cash paid at closing, and $500,000 to be paid
on the first day of the next calendar quarter, plus $250,000 to be paid on the first day of each successive calendar quarter until the
amount is paid in full.
Per
the Terms set forth in the Technology Rights Agreement, the consideration is defined as the sum of $10,000,000, consisting of $2,500,000
in cash at closing, and an additional $1,000,000 within 60 days after closing, and $6,500,000 worth of unrestricted common shares of
stock in the parent company, NSI, at a stipulated share price of $0.505. Determined with this stipulated price, 12,871,287 shares were
issued. Based on the market price on August 25, 2021 of $0.37, the fair value of the shares is $4,762,376, which results in a fair value
total consideration of $8,262,376.
As
of March 31, 2022, under both agreements, $4,750,000 had been paid, and for the years ended March 31, 2023 and 2022, $1,250,000 balance
is remaining unpaid.
The
terms of the Agreements set forth that NAS will pay Hydrenesis 12.5% royalty fees. The royalties are calculated per all customer or sub-license
revenue generated by NAS, NSI or any25 Affiliate, from the sale or rental of either the Technologies or Hydrenesis Equipment, based on
gross revenue less returns, rebates and sales taxes. There are sales milestones for exclusivity, whereby if NAS fails to achieve a sales
milestone starting in Year 3, the exclusivity rights in both of the Rights agreements shall revert to non-exclusive rights. To maintain
the exclusivity for the subsequent year, the Company may pay the amount of the royalty fees that would have been due if the Sales Milestone
had been meet in the current year.
The
Sales Milestones are:
SCHEDULE OF SALES MILESTONE
Year 3 | |
$ | 250,000 Royalty | |
Year 4 | |
$ | 375,000 Royalty | |
Year 5 | |
$ | 625,000 Royalty | |
Year 6 | |
$ | 875,000 Royalty | |
All subsequent years | |
$ | 1,000,000 Royalty | |
For
the years ended March 31, 2023 and 2022, the amortization of the Rights was $1,080,000 and $540,000, respectively. The amortization is
approximately $1,080,000 per year, and approximately $5,400,000 over the next five years.
NOTE
7 – SHORT-TERM NOTE AND LINES OF CREDIT
The
Company also has a working capital line of credit with Capital One Bank for $50,000. The line of credit bears an interest rate of prime
plus 25.9 basis points, which totaled 33.9% as of March 31, 2023. The line of credit is unsecured. The balance of the line of credit
was $9,580 at both March 31, 2023 and March 31, 2022.
The
Company also has a working capital line of credit with Chase Bank for $25,000. The line of credit bears an interest rate of prime plus
10 basis points, which totaled 18.0% as of March 31, 2023. The line of credit is secured by assets of the Company’s subsidiaries.
The balance of the line of credit is $10,237 as of March 31, 2023 and March 31, 2022.
NOTE
8 – PROMISSORY NOTE
January
2023 Note
On
January 20, 2023, the Company entered into a secured promissory note (“January 2023 Note”) with an investor (the “Investor”).
The January 2023 Note is in the aggregate principal amount of $631,968. The Note has an interest rate of 10% per annum, with a maturity
date nine months from the issuance date of the Note. The Note carried an original issue discount totaling $56,868, whereby the purchase
price is $575,100. All payments made by the Company under the terms in the note, including upon repayment of this Note at maturity, shall
be subject to an exit fee of 15% of the portion of the Outstanding Balance being paid (the “Exit Fee”). The cash was not
transferred to the Company’s bank account, but instead to the merger entity, Yotta Acquisition Corporation (Note 17), for a contribution
to a required extension fee for the business combination.
August
2022 Note
The
Company entered into a securities purchase agreement (the “SPA”) with an investor (the “Investor”) on August
17, 2022. Pursuant to the SPA, the Investor purchased a secured promissory note (the “Note”) in the aggregate principal amount
totaling approximately $5,433,333. The Note has an interest rate of 12% per annum, with a maturity date nine months from the issuance
date of the Note. The Note carried an original issue discount totaling $433,333 and a transaction expense amount of $10,000, both of
which are included in the principal balance of the Note. On the Closing Date the Company received $1,100,000, with $3,900,000 put into
escrow to be held until certain terms are met, which includes $3,400,000 upon the completion of a successful uplist to NYSE or NASDAQ.
The SPA includes a Security Agreement, whereby the note is secured by the collateral set forth in the agreement, covering all of the
assets of the Company. All payments made by the Company under the terms in the note, including upon repayment of this Note at maturity,
shall be subject to an exit fee of 15% of the portion of the Outstanding Balance being paid (the “Exit Fee”). As the Exit
Fee is to be included in every settlement of the Note, an additional 15% of the principal balance, which totals $816,500, was recognized
along with the principal balance, and offset by a contra account in a manner similar to a debt discount.
As
soon as reasonably possible, the Company will cause the Common Stock to be listed for trading on either of (a) NYSE, or (b) NASDAQ (in
either event, an “Uplist”). In the event the Company has not effectuated the Uplist by November 15, 2022, the then-current
outstanding balance will be increased by 10%. Following the Uplist, while the Note is still outstanding, ten days after the Company may
have a sale of any of its shares of common stock or preferred stock, there shall be a Mandatory Prepayment equal to the greater of $3,000,000
or thirty-three percent of the gross proceeds of the equity sale.
In
conjunction with the Merger Agreement, entered into on October 24, 2022, with Yotta Acquisition Corporation (Note 17), on November 4,
2022, the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note (the “August Note”),
through which the August Note was amended and restated in its entirety. The Restructuring Agreement included key modifications, in which
i) the Uplist terms were removed, ii) in the event that the Closing of the Merger does not occur on or before December 31, 2022, the
then-current Outstanding Balance will be increased by 2% and shall increase by 2% every 30 days thereafter until the Closing or termination
of the Merger Agreement, and iii) the outstanding balance of the Convertible Note may be increased by 5% to 15% upon the occurrence of
an event of default or failure to obtain the Lender’s consent or notify the Lender for certain major equity related transactions
(“Trigger Events”). The Merger has not yet closed, and therefore the 2% of the outstanding balance was increased as of March
31, 2023, in the amount of approximately $144,000.
The
Restructured August Note was analyzed under ASC 470-50 as to if the change in terms qualified as a modification or an extinguishment
of the note. The changes in terms were considered an extinguishment as the present value of the cash flows under the terms of the new
debt instrument was evaluated to be a substantial change, as over 10% difference from the present value of the remaining cash flows under
the terms of the original instrument. As such, with the removal of the original note and its debt discount and accrued interest as compared
to the restructured note with a fair value of approximately $1,933,000, there was a loss in extinguishment of approximately $157,000.
As a result of the extinguishment and at the Company’s election of the fair value option under ASC 825, the August Note will be
accounted for at fair value until they are settled. In accordance with ASC 815- 15-25-1(b) a hybrid instrument that is measured at fair
value under ASC 825 fair value option each period with changes in fair value reported in earnings as they occur should not be evaluated
for embedded derivatives. Therefore, the provisions in the August Note were not evaluated as to if they fell under the guidance of embedded
derivatives and were required to be bifurcated. The August Note was revalued as of March 31, 2023 at approximately $2,400,000, with a
change in fair value of approximately $467,000 recognized in the Statement of Operations.
NOTE
9 – CONVERTIBLE DEBENTURES
December
15, 2021 Debenture
The
Company entered into a securities purchase agreement (the “SPA”) with an investor (the “Investor”) on December
15, 2021. Pursuant to the SPA, the Investor purchased a secured promissory note (the “Note”) in the aggregate principal amount
totaling approximately $16,320,000 (the “Principal Amount”). The Note has an interest rate of 12% per annum, with a maturity
date 24 months from the issuance date of the Note (the “Maturity Date”). The Note carried an original issue discount totaling
$1,300,000 and a transaction expense amount of $20,000, both of which are included in the principal balance of the Note. The Note had
$2,035,000 in debt issuance costs, including fees paid in cash of $1,095,000 and 3,000,000 warrants issued to placement agents with a
fair value of $940,000. The warrant fair value was estimated using the Black Scholes Model, with the following inputs: the price of the
Company’s common stock of $0.32; a risk-free interest rate of 1.19%, the expected volatility of the Company’s common stock
of 209.9%; the estimated remaining term, a dividend rate of 0%. The warrants were classified as a liability, as it is not known if there
will be sufficient authorized shares to be issued upon settlement, based on the conversion terms of the convertible debt.
Beginning
on the date that is 6 months from the issuance date of the Note, the Investor has the right to redeem up to $1,000,000 of the outstanding
balance per month. Payments may be made by the Company, at the Company’s option, (a) in cash, or (b) by paying the redemption amount
in the form of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), per the following
formula: the number of redemption shares equals the portion of the applicable redemption amount divided by the Redemption Repayment Price.
The “Redemption Repayment Price” equals 90% multiplied by the average of the two lowest volume weighted average price per
share of the Common Stock during the ten (10) trading days immediately preceding the date that the Investor delivers notice electing
to redeem a portion of the Note. The redemption amount shall include a premium of 15% of the portion of the outstanding balance being
paid (the “Exit Fee”). As the Exit Fee is to be included in every settlement of the Note, an additional 15% of the principal
balance, which totals $2,448,000, was recognized along with the principal balance, and offset by a contra account in a manner similar
to a debt discount. In addition to the Investor’s right of redemption, the Company has the option to prepay the Notes at any time
prior to the Maturity Date by paying a premium of 15% plus the principal, interest, and fees owed as of the prepayment date.
Within
180 days of the issuance date of the Note, the Company will obtain an effective registration statement or a supplement to any existing
registration statement or prospectus with the SEC registering at least $15,000,000 in shares of Common Stock for the Investor’s
benefit such that any redemption using shares of Common Stock could be done using registered Common Stock. Additionally, as soon as reasonably
possible following the issuance of the Note, the Company will cause the Common Stock to be listed for trading on either of (a) NYSE,
or (b) NASDAQ (in either event, an “Uplist”). In the event the Company has not effectuated the Uplist by March 1, 2022, the
then-current outstanding balance will be increased by 10%. On February 7, 2022, the Company and the Lender entered into an amendment
to the SPA, which extended the date by which the Uplist must be completed to April 15, 2022. In consideration of the grant of the extension
there was an extension fee of $249,079 added to the principal balance, which has been recognized as a financing cost in the accompanying
consolidated financial statements. Subsequent to the year end, the date by which the Uplist had to be completed was further extended
to June 15, 2022, with no additional fee included. The Company will make a one-time payment to the Investor equal to 15% of the gross
proceeds the Company receives from the offering expected to be effected in connection with the Uplist (whether from the sale of shares
of its Common Stock and / or preferred stock) within ten (10) days of receiving such amount. In the event Borrower does not make this
payment, the then-current outstanding balance will be increased by 10%. In addition, the Company had 30 days in which to secure the Note
and grant the Lender a first position security interest in the real property in Texas and Iowa, and if it had not been effectuated within
the 30 days the outstanding balance would have been increased by 15%. The Company was required to reserve 65,000,000 shares of common
stock from its authorized and unissued common stock and to add 100,000,000 shares of common stock to the Share Reserve on or before March
10, 2022.
The
Note also contains certain negative covenants and Events of Default, which in addition to common events of default, include a failure
to deliver conversion shares, the Company fails to maintain the share reserve, the occurrence of a Fundamental Transaction without the
Lenders written consent, the Company effectuates a reverse split of its common stock without 20 trading days written notice to Lender,
fails to observe or perform or breaches any covenant, and, the Company or any of its subsidiaries, breaches any covenant or other term
or condition contained in any Other Agreements in any material. Upon an Event of a Default, at its option and sole discretion, the Investor
may consider the Note immediately due and payable. Upon such an Event of Default, the interest rate increases to 18% per annum and the
outstanding balance of the Note increases from 5% to 15%, depending upon the specific Event of Default. As of March 31, 2023 and 2022,
the Company is in full compliance with the covenants and Events of Default.
The
conversion feature met the definition of a derivative and therefore requires bifurcation and was accounted for as a derivative liability.
The Company estimated the fair value of the conversion feature derivative embedded in the debenture at issuance at $12,985,000, based
on assumptions used in a bi-nomial option pricing model. The key valuation assumptions used consist, in part, of the price of the Company’s
common stock of $0.305 at issuance date; a risk-free interest rate of 0.69% and expected volatility of the Company’s common stock,
of 125.90%, and the strike price of $0.3075.
On
November 4, 2022, the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note (the “Senior
Note”) with the December 2021 Investor through which the December 2021 Note was amended and restated in its entirety. These amendments
were made in conjunction with the Merger Agreement, entered into on October 24, 2022, with Yotta Acquisition Corporation (Note 17), The
main modification of the terms of the Senior Note was that the conversion feature was eliminated. Second, a Mandatory Payment was added
whereby within 3 trading days of the closing upon the Merger an amount equal to the lesser of (A) one-third of the amount retained in
the Trust Account at the Effective Time or (B) $10,000,000, in order to repay a portion of the outstanding balance of the Convertible
Note; after which the remaining balance of the Convertible Note is to be repaid in equal monthly installments over a 12-month period
beginning on a date after the Closing Date or the termination of such agreement. Additionally, if the Closing Date is after December
31, 2022, the outstanding balance of all indebtedness owed by the Company to December 2021 Investor will be increased automatically by
2% and will automatically increase by 2% every 30 days thereafter until the Closing, or substantially similar terms as approved by the
Board of Directors of the Company. Additional key modifications include i) the Uplist terms were removed, ii) Maturity date was modified
from December 15, 2023 to December 4, 2023, and iii) the outstanding balance of the Convertible Note may be increased by 5% to 15% upon
the occurrence of an event of default or failure to obtain the Lender’s consent or notify the Lender for certain major equity related
transactions (“Trigger Events”). As of March 31, 2023, the Merger has not yet closed, and therefore the 2% of the outstanding
balance was increased as of March 31, 2023, in the amount of approximately $1,336,000.
The
Restructured Senior Note was analyzed under ASC 470-50 as to if the change in terms qualified as a modification or an extinguishment
of the note. The changes in terms were considered an extinguishment as the conversion feature has been eliminated and therefore the modified
August Note is determined to be fundamentally different from the original convertible note. As such, with the removal of the original
note and its debt discount and accrued interest as compared to the restructured note with a fair value of approximately $18,914,000,
there was a gain in extinguishment of approximately $2,540,000. As of the restructuring date the derivative had a fair value of $12,290,000,
based on assumptions used in a bi-nomial option pricing model, which resulted in a change in fair value of $17,738,000 as of the restructuring
date, from its previous fair value of $30,028,000. The key valuation assumptions used consist, in part, of the price of the Company’s
common stock of $0.16 at issuance date; a risk-free interest rate of 3.73% and expected volatility of the Company’s common stock,
of 117.77%, and the strike price of $0.1017.
As
a result of the extinguishment and at the Company’s election of the fair value option under ASC 825, the Senior Note will be accounted
for at fair value until it is settled. In accordance with ASC 815- 15-25-1(b) a hybrid instrument that is measured at fair value under
ASC 825 fair value option each period with changes in fair value reported in earnings as they occur should not be evaluated for embedded
derivatives. Therefore, the provisions in the Senior Note were not evaluated as to if they fell under the guidance of embedded derivatives
and were required to be bifurcated. The Senior Note was revalued as of March 31, 2023, at approximately $21,290,000, with a change in
fair value of approximately $2,376,000 recognized in the Statement of Operations.
NOTE
10 – NOTES PAYABLE
On
December 15, 2020, in connection with the asset acquisition with VBF, the Company entered into two notes payable with a third party.
The first note, Promissory Note A, is for principal of $3,000,000, which is payable in 36 months with interest thereon at the rate of
5% per annum, interest only payable quarterly on the first day of the quarter, with the remaining balance to be paid to VBF as a balloon
payment on the maturity date. Promissory Note B, is for principal of $2,000,000, which is payable in 48 months with interest thereon
at the rate of 5% per annum, interest only payable quarterly on the first day of the quarter, with the remaining balance to be paid to
VBF as a balloon payment on the maturity date. On December 23, 2021, the Company paid off the two notes, for a discount of $4,500,000,
and recognized a gain on settlement of note, including accrued interest, of $815,943.
On
July 15, 2020, the Company issued a promissory note to Ms. Williams in the amount of $383,604 to settle the amounts that had been recognized
per the separation agreement with the late Mr. Bill Williams dated August 15, 2019 (Note 14) for his portion of the related party notes
and related accrued interest discussed above, and accrued compensation and allowances. The note bears interest at one percent per annum
and calls for monthly payments of $8,000 until the balance is paid in full. The balance as of March 31, 2023 and 2022 was $119,604 and
$215,604, respectively, with $96,000 classified in current liabilities for both year ends on the consolidated balance sheets.
NOTE
11 – ACQUISITION OF NON-CONTROLLING INTEREST
On
May 19, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with F&T, for the shares owned by F&T
of NAS. Upon the closing of the SPA, the Company purchased the 980,000 shares of NAS’ common stock owned by F&T for a total
acquisition price of $3,000,000, consisting of $1,000,000 paid in cash and 3,960,396 shares of the Company’s common stock issued
at a market value of $0.505 per share for a total fair value of $2,000,000. The Company paid the cash purchase price on May 20, 2021
and the purchase of the NAS shares closed on May 25, 2021. Prior to entering into the SPA, the Company owned fifty-one percent (51%)
and F&T owned forty-nine percent (49%) of the issued and outstanding shares of common stock of NAS, and therefore, NAS was included
in the consolidated financial statements of the Company, with F&T’s ownership accounted for as a non-controlling interest.
After the SPA, the non-controlling interest was no longer in existence and NAS became a 100% owned subsidiary of the Company. In accordance
with ASC 810-10-45, when the parent’s ownership interest changes while the parent retains its controlling interest in a subsidiary,
it is accounted for as an equity transaction and there is no gain or loss recognized in the consolidated net loss. The difference between
the fair value of the consideration paid and the amount of the non-controlling interest as of the acquisition of NAS shares held by F&T
is recognized in equity attributable to the Company. The carrying amount of the non-controlling interest prior to the acquisition was
a deficit of $87,830, and as a result, a deduction of $3,087,830 was recognized in additional paid in capital in the Consolidated Statement
of Changes in Equity, in the year ended March 31, 2022.
NOTE
12 – STOCKHOLDERS’ EQUITY
Preferred
Stock
As
of March 31, 2023 and March 31, 2022, the Company had 200,000,000
shares of preferred stock authorized with a par
value of $0.0001.
Of this amount, 5,000,000
shares of Series A Preferred Stock are authorized
and outstanding, 5,000
shares Series B Preferred Stock are authorized
no
shares outstanding; 5,000
shares Series D Preferred Stock are authorized
with no
outstanding; 10,000
shares Series E Preferred Stock are authorized
with 1,670
and 2,840
outstanding, respectively; and 750,000
shares Series F Redeemable Convertible Preferred
stock are authorized with 750,000
shares outstanding, respectively.
Series
B Preferred Stock
On
September 5, 2019, the Board authorized the issuance of 5,000 preferred shares to be designated as Series B Preferred Stock. The Series
B Preferred Stock have a par value of $0.0001, a stated value of $1,200 and no voting rights. The Series B Preferred Stock included 10%
cumulative dividends, payable quarterly. Upon the dissolution, liquidation or winding up of the Company, the holders of Series B Preferred
Stock would be entitled to receive out of the assets of the Company an amount equal to the stated value, plus any accrued and unpaid
dividends and any other fees or liquidated damages then due and owing for each share of Series B Preferred Stock before any payment or
distribution shall be made to the holders of any Junior securities. The Series B Preferred Stock were redeemable at the Company’s
option, at percentages ranging from 120% to 135% for the first 180 days, based on the passage of time. The Series B were also redeemable
at the holder’s option, upon the occurrence of a triggering event which includes a change of control, bankruptcy, and the inability
to deliver Series B Preferred Stock requested under conversion notices. The triggering redemption amount is at the greater of (i) 135%
of the stated value or (ii) the product of the volume-weighted average price (“VWAP”) on the day proceeding the triggering
event multiplied by the stated value divided by the conversion price. As the redemption feature at the holder’s option was contingent
on a future triggering event, the Series B Preferred Stock was considered contingently redeemable, and as such the preferred shares were
classified in equity until such time as a triggering event would occur, at which time they would be classified as mezzanine.
The
Series B Preferred Stock was convertible, at the discounted market price which is defined as the lowest VWAP over last 20 days. The conversion
price would be adjustable based on several situations, including future dilutive issuances. As the Series B Preferred Stock did not have
a redemption date and is perpetual preferred stock, it was considered to be an equity host instrument and as such the conversion feature
was not required to be bifurcated as it was clearly and closely related to the equity host instrument.
Series
B Preferred Equity Offering
On
September 17, 2019, the Company entered into a Securities Purchase Agreement (“SPA”) with GHS Investments LLC, a Nevada limited
liability company (“GHS”) for the purchase of up to 5,000 shares of Series B Preferred Stock at a stated value of $1,200
per share, or for a total net proceeds of $5,000,000 in the event the entire 5,000 shares of Series B Preferred Stock are purchased.
During the year ended March 31, 2020, the Company issued 2,250 Series B Preferred Shares in various tranches of the SPA, totaling $2,250,000.
During the year ended March 31, 2021 the Company received $3,250,000 for the issuance of 3,250 Series B Preferred Stock. During the year
ended March 31, 2021, the Company converted 5,008 Series B Preferred Stock which includes 115 Series B Preferred Stock dividends-in-kind
into 113,517,030 shares of the Company’s common stock. During the year ended March 31, 2022, the Company converted the remaining
607 Series B Preferred Stock plus 232 Series B Preferred Stock dividends-in-kind into 10,068,000 shares of the Company’s common
stock.
Series
D Preferred Stock
On
December 16, 2020, the Board authorized the issuance of 20,000 preferred shares to be designated as Series D Preferred Stock. The Series
D Preferred Stock have a par value of $0.0001, a stated value of $1,200 and would vote together with the common stock on an as-converted
basis. Each holder of Series D Preferred Stock was entitled to receive, with respect to each share of Series D Preferred Stock then outstanding
and held by such holder, dividends at the rate of twelve percent (12%) per annum (the “Preferred Dividends”). Dividends may
be paid in cash or in shares of Preferred Stock at the discretion of the Company.
The
Series D Preferred Stock were convertible into Common Stock at the election of the holder of the Series D Preferred Stock at any time
following five days after a qualified offering (defined as an offering of common stock for an aggregate price of at least $10,000,000
resulting in the listing for trading of the Common Stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market or the New York Stock Exchange) at a 35% discount to the offering price, or, if a qualified offering has
not occurred, at a price of $0.10 per share, subject to adjustment based on several situations, including future dilutive issuances and
a Fundamental Transaction.
The
Series D Preferred Stock were to be redeemed by the Corporation on the date that was no later than one calendar year from the date of
its issuance. The Company was to redeem the Series D Preferred Stock in cash upon a three business days prior notice to the holder or
the holder may convert the Series D Preferred Stock within such three business days period prior to redemption. Additionally, the holder
had the right to either redeem for cash or convert the Preferred Stock into Common Stock within three business days following the consummation
of a qualified offering. The Series D Preferred Stock were also redeemable at the holder’s option, upon the occurrence of a triggering
event which includes a change of control, bankruptcy, and the inability to deliver shares of common stock requested under conversion
notices. The triggering redemption amount would be 150% of the stated value.
Series
D Preferred Equity Offering
On
December 18, 2020, the Company entered into securities purchase agreements (the “Purchase Agreement”) with GHS Investments
LLC, Platinum Point Capital LLC and BHP Capital NY (collectively, the “Purchaser”) , whereby, at the closing, each Purchaser
agreed to purchase from the Company, up to 5,000 shares of the Company’s Series D Preferred Stock, par value $0.0001 per share,
at a purchase price of $1,000 per share of Series D Preferred Stock. The aggregate purchase price per Purchaser for the Series D Preferred
Stock is $5,000,000. With a stated value of $6,000,000 for the purchased Series D Preferred Stock, there was a discount of $1,000,000
that was accreted over the period until the redemption of the Series D Preferred Stock.
On
January 8 and 10, 2021, the Company entered into additional securities purchase agreements with the Purchaser, for 1,050 shares of Series
D Preferred Stock, at an aggregate purchase price of $1,050,000. With a stated value of $1,250,000 for the purchased Series D Preferred
Stock, there was a discount of $250,000 that was accreted over the period until the redemption of the Series D Preferred Stock.
In
addition, in relation to the share exchange agreement (described below), on April 15, 2021, the Company redeemed the remaining 2,450
of the Series D Preferred Stock for $3,513,504. In accordance with ASC 260-10-S99-2, the difference between the fair value of the consideration
transferred to the holder of the Series D Preferred Stock and the carrying amount of the Series D Preferred Stock immediately prior to
the redemption, which was $2,534,758, was accounted for in a manner similar to a dividend.
Series
E Preferred Stock
On
April 14, 2021, the Board authorized the issuance of 10,000 shares of the Company’s Series E Preferred Stock and has filed a Certificate
of Designation (“COD”) of Preferences of the Series E Convertible Preferred Stock with the State of Nevada. The shares of
Series E Preferred Stock have a stated value of $1,200 per share and are convertible into shares of common stock at the election of the
holder of the Series E Preferred Stock at any time at a price of $0.35 per share, subject to adjustment (the “Conversion Price”).
The Series E Preferred Stock is convertible into that number of shares of common stock determined by dividing the Series E Stated Value
(plus any and all other amounts which may be owing in connection therewith) by the Conversion Price, subject to certain beneficial ownership
limitations. Each holder of Series E Preferred Stock shall be entitled to receive, with respect to each share of Series E Preferred Stock
then outstanding and held by such holder, dividends at the rate of twelve percent (12%) per annum, payable quarterly. Each share of Series
E Preferred Stock shall be redeemed by the Company on the date that is no later than one calendar year from the date of its issuance.
The Series E Preferred Stock are also redeemable at the Company’s option, at percentages ranging from 115% to 125% for the first
180 days, based on the passage of time. The holders of Series E Preferred Stock rank senior to the Common Stock and Common Stock Equivalents
(as defined in the Series E Designation) with respect to payment of dividends and rights upon liquidation and will vote together with
the holders of the Common Stock on an as-converted basis, subject to beneficial ownership limitations, on each matter submitted to a
vote of holders of Common Stock (whether at a meeting of shareholders or by written consent). Based upon a subsequent financing, the
holder has the option to exchange (in lieu of conversion), all or some of the shares of Series E Preferred Stock then held for any securities
or units issued in a subsequent financing on a $1.00 for $1.00 basis. In the event of a Fundamental Transaction, the holder has the option
to request that the Company or the successor entity shall purchase the Preferred Stock from the Holder on the date of such request by
paying to the Holder cash in an amount equal to the Black Scholes value. Upon any triggering event as set forth in the COD, including
a change in control or the Company shall fail to have available a sufficient number of authorized and unreserved shares of common stock
to issue to such holder upon a conversion, each holder shall have the right, exercisable at the sole option of such holder, to require
the Company to redeem all of the Series E Preferred Stock then held by such holder for a redemption price, in cash, equal to the Triggering
Redemption Amount (150% of the Stated Value and all accrued but unpaid dividends and all liquidated damages, late fees and other costs),
and increase the dividend rate on all of the outstanding Preferred Stock held by such Holder to 18% per annum thereafter. Upon any liquidation,
dissolution or winding-up of the Company, the holders shall be entitled to receive out of the assets of the Company an amount equal to
the stated value, plus any accrued and unpaid dividends and any other fees or liquidated damages then due and owing for each share of
Preferred Stock, before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation
shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be ratably distributed
among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were
paid in full.
On
November 22, 2021, the Company entered into a securities purchase agreement (“SPA”) for 1,500 shares of the Company’s
Series E Preferred Stock, at a price of $1,000 per share and (ii) a warrant to purchase up to 1,500,000 shares of the Company’s
common stock, with an exercise price equal to $0.75, which expires in five years, for a purchase price of $1,500,000. The warrant has
a fair value of $561,000, estimated using the Black Scholes Model, with the following inputs: the price of the Company’s common
stock of $0.38; a risk-free interest rate of 1.33%, the expected volatility of the Company’s common stock of 209.9%; the estimated
remaining term, a dividend rate of 0%. The Company also issued 267,429 warrants as placement agent fees, with a fair value of $101,000,
estimated with the same assumptions. All of the warrants were classified as a liability, as it is not known if there will be sufficient
authorized shares to be issued upon settlement, based on the conversion terms of the convertible debt. The Company analyzed the conversion
feature under ASC 470-20, “Debt with conversion and other options”, and based on the market price of the common stock of
the Company on the dates of funding as compared to the conversion price, determined there was a beneficial conversion feature of approximately
$170.000 to recognize, which was amortized over the term through the redemption date using the effective interest method. The Company
will accrete the carrying value, reflecting the discount of $300,000 between the stated value and purchase price and the fair value of
the warrants issued of $662,000, of the Series E Preferred Stock in temporary equity up to the redemption value over the period until
its redemption. For the years ended March 31, 2023 and 2022, respectively, approximately $755,000 and $338,000 was accreted, and was
fully accreted as of March 31, 2023.
On
April 14, 2021, the Company, entered into a share exchange agreement (the “Exchange Agreement”) with a holder of the Series
D Preferred Stock, whereby, at the closing of the Offering, the Holder agreed to exchange an aggregate of 3,600 shares of the Company’s
Series D Preferred Stock, par value $0.0001 per share into 3,739.63 shares of the Company’s Series E Convertible Preferred stock,
par value $0.0001 (the “Series E Preferred Stock”). The exchange was completed on April 15, 2021. In accordance with ASC
260-10-S99-2, exchanges of preferred stock that are considered to be extinguishments are to be accounted for as a redemption. Therefore,
the difference between the fair value of the Series E Preferred Stock transferred to the holder of the Series D Preferred Stock and the
carrying amount of the Series D Preferred Stock immediately prior to the exchange, which was $3,258,189, was accounted for in a manner
similar to a dividend.
The
Company analyzed the conversion feature of the Series E Preferred Stock issued on April 14, 2021, under ASC 470-20, “Debt with
conversion and other options”, and based on the market price of the common stock of the Company on the dates of funding as compared
to the conversion price, determined there was a beneficial conversion feature of approximately $3,270,000 to recognize, which will be
amortized over the term of the note using the effective interest method. During the year ended March 31, 2022, the total Series E Preferred
Stock BCF amortization, including the November 22, 2021, SPA, was $3,326,172.
On
June 16, 2022, one of the holders of the Series E Convertible Preferred Stock chose to exercise their right, pursuant to the Certificate
of Designation relating to the Series E Convertible Preferred Stock, to receive the rights extended to the convertible noteholder, of
90% multiplied by the average of the two lowest volume weighted average price per share of the Common Stock during the ten (10) trading
days immediately preceding the date of conversion. As the exercise of the conversion price adjustment was similar to a down round, and
the Company has not yet adopted ASU 2020-06, the accounting treatment of ASU 2017-11 was applied, whereby the adjustment was treated
as a contingent beneficial conversion feature recognized as of the triggering date. As of June 16, 2022, this holder held 940 shares
of the Series E preferred stock. The Company analyzed the conversion feature under ASC 470-20, “Debt with conversion and other
options”, and based on the market price of the common stock of the Company as compared to the conversion price, determined there
was a $99,000 beneficial conversion feature to recognize, which was fully amortized as there is no remaining redemption date to their
Series E Preferred Stock. The additional rights of the convertible note which were applied include the 10% increase in the outstanding
balance if an uplist to a national exchange was not consummated by the Company by March 1, 2022, for an increase of 130 Series E Preferred
shares with a stated value of $156,000, as well as an exit fee of 15% to be recognized upon conversions of the Series E Preferred shares
into shares of common stock. As of March 31, 2023, 170 shares of Series E Preferred Stock are outstanding to this holder.
During
the year ended March 31, 2023, 1,300
shares of Series E Preferred Stock were converted
into 14,458,127
shares of common stock. During the year ended
March 31, 2022, 2,400
shares of Series E Preferred Stock were converted
into 8,228,572
shares of common stock. As of March 31, 2023
there are 1,670
shares of Series E Preferred Stock remaining
outstanding.
On
November 5, 2022, the Company entered a restructuring agreement with the Series E Preferred Stockholders, whereby the Series E Preferred
Stock and the warrants outstanding (including all holders of the warrants in Note 13) as of the Closing date shall have their terms adjusted.
The outstanding warrants shall be a) cancelled in exchange for a cash payment equal to the fair value of the warrants based on the Black
Scholes model, with the exercise price to be adjusted to equal 80% of the average volume weighted average price of the Company common
stock during the five trading day period immediately prior to the Closing Date (the “Adjusted Exercise Price”); or (b) as
of the Effective Time, canceled and treated as if exercised for that number of shares of the Company’s common stock calculated
using the Black Scholes model fair value, the number of Warrant Shares on the Closing Date and the Adjusted Exercise Price, with the
shares of the Company’s common stock that would have been due to Holder as a result of such exercise of the Warrant treated as
if issued to Holder and then converted into the right to receive (i) the Closing Per Share Merger Consideration (as defined in the Merger
Agreement) plus (ii) the Additional Per Share Merger Consideration (as defined in the Merger Agreement), if any, at the time and subject
to the contingencies set forth in the Merger Agreement. For the Series E Preferred Stock that shall be outstanding immediately prior
to the Effective Time, they shall be canceled and treated as if converted into that number of shares of the Company’s common stock
equal to (i) the stated value of $1,200 per share plus any unpaid dividends, multiplied by 1.25, divided by (ii) 80% of the average volume
weighted average price of the Company’s common stock during the five trading day period immediately prior to the Closing Date.
The shares of the Company’s common stock that would have been due to the holder as a result of the conversion of such shares of
Series E Convertible Preferred Stock shall be treated as issued to holder and converted, as of the Effective Time, into the right to
receive (y) the Closing Per Share Merger Consideration plus (z) the Additional Per Share Merger Consideration, if any, at the time and
subject to the contingencies set forth in the Merger Agreement.
Series
F Preferred Stock
On
February 22, 2022, the Board of Directors authorized Series F Preferred Stock and filed the Certificate of Designation with Nevada. The
Series F Preferred Stock have a par value of $0.0001. The Series F Designation authorized the issuance of up to 750,000 shares of the
Company’s Series F Convertible Preferred Stock. At any time after the three year anniversary of the issuance of the shares of Series
F Preferred Stock (the “Issuance Date”), each individual holder shall have the right, at each individual holder’s sole
option, to convert all of the shares of Series F Preferred Stock that such individual holds into shares of fully paid and nonassessable
shares of common stock in an amount equal to 8% of the Company’s issued and outstanding shares of common stock. Each individual
holder of Series F Preferred Stock may only convert all of their shares of Series F Preferred Stock in one transaction. On any matter
presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company each holder
of outstanding shares of Series F Preferred Stock will cast 1,000 votes per each share of Series F Preferred Stock held by such holder.
The holders are not entitled to receive dividends, nor are they entitled to receive any distributions in the event of any liquidation,
dissolution or winding down of the Company, either voluntarily or involuntarily. The Company determined that the conversion feature was
not required to be bifurcated as the conversion provision was determined to be clearly and closely related to the Series F Preferred
Stock host instrument.
In
the case of any capital reorganization, any reclassification of the stock of the Company, or a Change in Control, the shares of Series
F Preferred Stock shall, at the effective time of such reorganization, reclassification, or Change in Control, be automatically converted
into the kind and number of shares of stock or other securities or property of the Company or of the entity resulting from such reorganization,
reclassification, or Change in Control to which such holder would have been entitled if immediately prior to such reorganization, reclassification,
or Change in Control it had converted its shares of Series F Preferred Stock into common stock.
On
March 1, 2022, the Board of Directors of the Company issued 250,000 shares of Series F Preferred Stock to each of Gerald Easterling,
William Delgado and Thomas Untermeyer in consideration for their past and future services as executive officers of the Company, for a
total of 750,000 shares of Series F Preferred Stock. The fair value of the stock compensation has been recognized based on the estimated
value of the instruments the Company would be obligated to provide to the holders upon conversion to common shares, which for all three
holders of Series F Preferred Stock would reflect 24% of the fair value of the outstanding common shares as of the grant date of March
1, 2022. Based on the number of outstanding shares of common stock plus shares payable, of 738,687,135, and the market value of the common
stock of $0.246 on that date, the total stock compensation was $43,612,000. In accordance with ASC 718, as the shares are fully vested
on the grant date, as well as all services required to be provided have occurred, the stock compensation was immediately recognized.
Common
Stock
For
shares of common stock issued upon conversion of outstanding convertible debentures see Note 9.
Securities
Purchase Agreement
On
April 14, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor
(the “Purchaser”), for the offering (the “Offering”) of (i) $5,000,000 worth of common stock (“Shares”),
par value $0.0001 per share, of the Company (“Common Stock”); at a per share purchase price of $0.55 per Share (ii) common
stock purchase warrants (“Warrants”) to purchase up to an aggregate of 10,000,000 shares of Common Stock, which are exercisable
for a period of five years after issuance at an initial exercise price of $0.75 per share, subject to certain adjustments, as provided
in the Warrants; and (iii) 1,000,000 shares of Common Stock (the “Commitment Shares”). Pursuant to the Purchase Agreement,
on April 15, 2021, the Company received net proceeds of $4,732,123 from the Purchaser.
Further,
pursuant to the terms of the Purchase Agreement, from the date thereof until the date that is the twelve-month anniversary of the closing
of the Offering, upon any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock Equivalents for cash consideration,
indebtedness or a combination of units thereof (a “Subsequent Financing”), each Purchaser shall have the right to participate
in up to an amount of the Subsequent Financing equal to 100% of the Subsequent Financing on the same terms, conditions and price provided
for in the Subsequent Financing.
Pursuant
to the Purchase Agreement, on May 5, 2021, the Purchaser purchased an additional 15,454,456 shares of common stock at a per share purchase
price of $0.55 per share (the “Second Closing”), for net proceeds of approximately $8,245,000.
Additionally,
on May 20, 2021, the Purchaser purchased an additional 2,727,272 shares of common stock at a price per share of $0.55 per share (“Third
Closing”), for net proceeds of approximately $1,455,000.
On
November 22, 2021, in relation to the SPA with a different holder for 1,500 shares of the Company’s Series E Preferred Stock, GHS
entered into a waiver, whereby they waived their right to participate in a subsequent filing. Additionally, the exercise price on the
existing warrants to purchase 10,000,000 shares of common stock was reduced to $0.35, as well as the issuance of warrants to purchase
3,739,000 shares of common stock warrants, with an exercise price of $0.75. The modification on the change in the exercise price of the
warrants was estimated on November 22, 2021, by comparison of the fair value of the warrants with the original exercise price to the
fair value with the new exercise price, using Black Scholes Model, with the following inputs: the price of the Company’s common
stock of $0.38; a risk-free interest rate of 1.33%, the expected volatility of the Company’s common stock of 209.9%; the estimated
remaining term, a dividend rate of 0%, with a essentially no change in fair value. The newly issued warrants had a fair value of $1,373,000,
which was estimated using the Black Scholes Model, with the same inputs, including the exercise price of $0.75. The warrants fair value
has been recognized as a liability, based on the fact it as it is not known if there will be sufficient authorized shares to be issued
upon settlement, based on the conversion terms of the existing convertible debt, with the April 12, 2021 warrants reclassed from equity
to warrant liability, and the newly issued warrants liability recognized as financing costs.
GHS
2021 Purchase Agreement
On
June 28, 2021, the Company entered into a securities purchase agreement with GHS (the “June GHS Purchase Agreement”) for
the offering of up to (i) $3,000,000 worth of common stock of the Company at a per share purchase price of $0.40 and (ii) $11,000 worth
of prefunded common stock purchase warrants to purchase an aggregate of up to 1,100,000 shares of common stock, which are exercisable
upon issuance and shall not expire prior to exercise, and are subject to certain adjustments, as provided in the warrants. Pursuant to
the GHS 2021 Purchase Agreement, on June 28, 2021, GHS purchased 7,500,000 shares of common stock and 1,100,000 shares of common stock
underlying the prefunded warrants, for an aggregate purchase price of $3,011,000, less offering expenses of $90,330, for net proceeds
of $2,909,670.
GHS
2022 Purchase Agreement
On
November 4, 2022, the Company entered into a purchase agreement (the “GHS Purchase Agreement”) with GHS Investments LLC (“GHS”),
an accredited investor, pursuant to which, the Company may require GHS to purchase a maximum of up to 64,000,000 shares of the Company’s
common stock (“GHS Purchase Shares”) based on a total aggregate purchase price of up to $5,000,000 over a one-year term that
ends on November 4, 2023. Notwithstanding the foregoing dollar limitations, the Company and GHS
may, from time to time, mutually agree in writing to waive the aforementioned limitations for a relevant Purchase Notice, which waiver,
shall not exceed the 4.99% beneficial ownership limitation contained in the GHS 2022 Purchase Agreement. The Company is to control
the timing and amount of any sales of GHS Purchase Shares to GHS. The Company intends to use the net proceeds from this offering for
working capital and general corporate purposes.
The
“Purchase Price” means, with respect to a purchase made pursuant to the GHS Purchase Agreement, 90% of the lowest VWAP during
the 10 consecutive business days immediately preceding, but not including, the applicable purchase date. The Company shall deliver a
number of GHS Purchase Shares equal to 112.5% of the aggregate purchase amount for such GHS Purchase divided by the Purchase Price per
share for such GHS Purchase.
If
there are any default events, as set forth in the GHS Purchase Agreement, has occurred and is continuing, the Company shall not deliver
to GHS any Purchase Notice.
Further,
pursuant to the terms of the GHS Purchase Agreement, from November 4, 2022 until the date that is the later of (i) the closing of the
transactions whereby Yotta Merger Sub, Inc. will merge with and into the Company, with the Company as the surviving company (the “Merger”);
and (ii) the 12 month anniversary of the first delivery of GHS Purchase Shares, upon any issuance by the Company or any of its subsidiaries
of Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent
Financing”), GHS shall have the right to participate in any financing, up to an amount of the Subsequent Financing equal to 100%
of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent
Financing. Following the Merger, the Participation Maximum shall be 50% of the Subsequent Financing.
In
the year ended March 31, 2023, the Company sold 52,018,294 shares of common stock at a net amount of approximately $3,076,000, at share
prices ranging from $0.04 to $0.10.
Common
Shares Issued to Consultants
On
August 1, 2022, the Company issued 250,000 shares of common stock to a consultant per the terms of an agreement from June 2021, to be
issued upon the approval of a patent.
During
the three months ended December 31, 2021, three consultants were issued a total of approximately 430,000 shares of common stock, with
a total fair value of approximately $158,000, based on the market price of $0.36 on the grant date.
On
April 14, 2021, 500,000 shares of common stock were issued to a consultant per an agreement entered into on January 20, 2021 for advisory
services for a two-year period. The shares had a fair value of $195,000, based on the market price of $0.39 on the grant date. A total
of 62,500 common shares vested each quarter through October 1, 2022.
On
May 24, 2021, the Company entered into an agreement with a consultant, with a three-month term, that shall automatically renew each three
months unless one party terminates the agreement. The compensation shall be $12,500 in cash per month for the first six months and $15,000
per month thereafter. Also included in compensation are 200,000 shares of common stock, with a fair value of $99,600 based upon the market
price of $0.50 upon the grant date. The shares of common stock will vest in quarterly installments, with 50,000 to vest immediately,
and 50,000 each quarter at $24,900, and was fully vested by the year end March 31, 2022.
Common
Stock Issued in Relation to Business Agreement
As
of June 22, 2022, 250,000 common shares were issued in relation to a trial distribution agreement entered into with a consultant who
was to introduce the Company to customers. Additionally, the consultant was also to assist the Company in the set-up of ancillary materials
used or useful in the delivery of live shrimp, including installation of necessary equipment and facilities, logistical support, training
of staff and packaging necessary for shipment of live shrimp. After the result of the trial period, the parties could have, but decided
not to, negotiate and execute a long-term distribution agreement. The shares will be paid for by the Company withholding sufficient profits
from the sale of the live shrimp to the customers introduced by the consultant.
Common
Shares Issued to Employees
During
the year ended March 31, 2022, a number of new employees were granted a total of 375,000 shares of common stock as signing bonuses, with
275,000 issued, with a total fair value of approximately $108,000, based on the market price of $0.395 on the grant date, with 100,000
of the shares issued in the year ending March 31, 2023.
NOTE
13 – OPTIONS AND WARRANTS
The
Company has not granted any options since inception.
On
April 14, 2021, the Company entered into a securities purchase agreement in which 10,000,000 warrants were also issued, which are exercisable
for a period of five years after issuance at an initial exercise price of $0.75 per share, subject to certain adjustments, as provided
in the Warrants (see Note 12 for more discussion)
Additionally,
as noted in Note 12, on November 22, 2021, 3,739,000 shares of common stock warrants, with an exercise price of $0.75, were issued in
relation to a waiver. As part of the waiver, the exercise price on the existing warrants to purchase 10,000,000 shares of common stock
was reduced to $0.35.
In
connection with the November 22, 2021 sale of Series E Preferred Stock (Note 12), 1,500,000 options were issued, as well as approximately
270,000 warrants were issued to placement agents. Additionally, in relation to the December 15, 2021, convertible note (Note 9) there
were 3,000,000 warrants issued to placement agents with a fair value.
No
warrants were issued in the year ended March 31, 2023, nor were any warrants exercised nor expired. The outstanding warrants have an
average strike price of $0.47, with remaining terms from 3 years to 3.72 years.
All
of the warrants issued have been recognized as a liability, based on the fact it as it is not known if there will be sufficient authorized
shares to be issued upon settlement.
The
18,573,116 warrants outstanding as of March 31, 2023, were revalued as of year-end for a fair value of $355,000, with a decrease in the
fair value of $3,568,000 recognized on the Statement of Operations. The fair value was estimated using Black Scholes Model, with the
following inputs: the price of the Company’s common stock of $0.05; a risk-free interest rate of 3.81%, the expected volatility
of the Company’s common stock of 121.0%; the estimated remaining term, a dividend rate of 0%,
NOTE
14 – RELATED PARTY TRANSACTIONS
Accrued
Payroll – Related Parties
The
accrued expenses, related party, on the accompanying consolidated balance sheets represents accrued payroll and payroll taxes, and the
bonus discussed below. Included in other accrued expenses on the accompanying consolidated balance sheet as of March 31, 2022, is approximately
$119,000 owing to Chief Technology Officer (“CTO”) (which includes $50,000 from consulting services prior to his employment),
including both accrued payroll and accrued allowances and expenses. In the current year the CTO forgave the prior amounts owed to him,
with a gain on settlement of accrued expenses recognized in the year ended March 31, 2023 consolidated statement of operations.
Bonus
Compensation – Related Party
On
May 11, 2021, the Company paid the Chief Financial Officer (“CFO”) a bonus of $300,000. On August 10, 2021, the Board of
Directors ratified the bonus payment to the CFO and awarded the President and the CTO compensation bonuses of $300,000 each. The bonuses
to the President and CTO are to be distributed within the next twelve months from the award date, and are included in accrued expenses,
related parties as of December 31, 2021. During the year ended March 31, 2022, $200,000 was paid each to the President and CTO, with
a total of $200,000 remaining in accrued expenses, related parties, as of March 31, 2023 and 2022.
NaturalShrimp
Holdings, Inc.
On
January 1, 2016 the Company entered into a notes payable agreement with NaturalShrimp Holdings, Inc.(“NSH”), a shareholder.
The note payable has no set monthly payment or maturity date with a stated interest rate of 2%. During the year ended March 31, 2022,
the Company paid off $655,750 of the note payable. The outstanding balance is approximately $77,000 as of both March 31, 2023 and March
31, 2022. As of both March 31, 2023 and March 31, 2022, accrued interest payable was approximately $74,000.
Promissory
Note
On
August 10, 2022, the Company issued a loan agreement for $300,000, with related parties, which is to be considered priority debt of the
Company. As of this filing, five of the related parties have entered into promissory notes under the loan agreement for $50,000 each,
for a total of cash received of $250,000. The notes bear interest at a 10% per annum and are due in one year from the issuance date of
the notes. For the year ended March 31, 2023, the interest expense was $22,270.
Shareholder
Notes
The
Company has entered into several working capital notes payable to multiple shareholders of NSH and Bill Williams, a former officer and
director, and a shareholder of the Company, for a total of $486,500. The notes are unsecured and bear interest at 8%. These notes had
stock issued in lieu of interest and have no set monthly payment or maturity date. The balance of these notes was $356,404 as of March
31, 2023 and 2022, respectively, and is classified as a current liability on the consolidated balance sheets. As of March 31, 2023 and
March 31, 2022, accrued interest payable was approximately $146,000.
Shareholders
Beginning
in 2010, the Company started entering into several working capital notes payable with various shareholders of NSH for a total of $290,000
and bearing interest at 8%. The balance of these notes as of March 31, 2023 and March 31, 2022 was $54,647 and is classified as a current
liability on the consolidated balance sheets.
NOTE
15 – FEDERAL INCOME TAX
The
Company accounts for income taxes under ASC 740-10, which provides for an asset and liability approach of accounting for income taxes.
Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently
enacted tax laws, attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts calculated for income tax purposes.
The
components of income tax expense for the years ended March 31, 2023 and 2022 consist of the following:
SCHEDULE
OF INCOME TAX EXPENSE
| |
2023 | | |
2022 | |
Federal Tax statutory rate | |
| 21.0 | % | |
| 21.0 | % |
Permanent differences | |
| 4.6 | % | |
| 18.4 | % |
Valuation allowance | |
| (25.6 | )% | |
| (39.4 | )% |
Effective rate | |
| 0.0 | % | |
| 0.0 | % |
Significant
components of the Company’s deferred tax assets as of March 31, 2023 and 2022 are summarized below.
SCHEDULE
OF DEFERRED TAX ASSET
| |
2023 | | |
2022 | |
Deferred tax assets: | |
| | | |
| | |
Net operating loss carryforwards | |
$ | 8,900,000 | | |
$ | 6,022,000 | |
Other | |
| (279,000 | ) | |
| (350,000 | ) |
Total deferred tax asset | |
| 8,621,000 | | |
| 5,672,000 | |
Valuation allowance | |
| (8,621,000 | ) | |
| (5,672,000 | ) |
Total | |
$ | - | | |
$ | - | |
As
of March 31, 2023, the Company had approximately $42,500,000 of federal net operating loss carry forwards. The carry forwards beginning
in tax years 2018 are allowed to be carried forward indefinitely and are to be limited to 80% of the taxable income. Future utilization
of the net operating loss carry forwards is subject to certain limitations under Section 382 of the Internal Revenue Code. The Company
believes that the issuance of its common stock in exchange for Multiplayer Online Dragon, Inc. on January 30, 2015 resulted in an “ownership
change” under the rules and regulations of Section 382. Accordingly, the Company’s ability to utilize their net operating
losses generated prior to this date is limited to approximately $282,000 annually.
To
the extent that the tax deduction is included in a net operating loss carry forward and is in excess of amounts recognized for book purposes,
no benefit will be recognized until the loss carry forward is recognized. Upon utilization and realization of the carry forward, the
corresponding change in the deferred asset and valuation allowance will be recorded as additional paid-in capital.
The
Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets.
The Company has established a valuation allowance against the net deferred tax asset due to the uncertainty that enough taxable income
will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred
tax assets in the accompanying financial statements. The Company’s net deferred tax asset and valuation allowance increased by
$5,192,000 and $2,243,000 in the years ended March 31, 2023 and 2022, respectively.
The
Company reviewed all income tax positions taken or that they expect to be taken for all open years and determined that the income tax
positions are appropriately stated and supported for all open years. The Company is subject to U.S. federal income tax examinations by
tax authorities for years after 2023 due to unexpired net operating loss carryforwards originating in and subsequent to that year. The
Company may be subject to income tax examinations for the various taxing authorities which vary by jurisdiction.
NOTE
16 – LEASE
On
May 26, 2021, the Company entered into a sublease for a new office space in Texas, on two floors. The lease commenced on August 1, 2021
for a monthly rent of $7,000, and will terminate on October 31, 2025, for one of the spaces, and commence in the second half of 2022
for monthly rent of $1,727, and terminate on October 31, 2025, for the second space. On June 2, 2021, the Company paid a deposit of $52,362
which shall be applied to the last six months of the sublease term, and $17,454 security deposit, which is included in Prepaid expenses
on the accompanying consolidated balance sheet. The Company assessed its new office lease as an operating lease.
At
inception, on August 1, 2021, the ROU and lease liability was calculated as approximately $316,000, based on the net present value of
the future lease payments over the term of the lease. When available, the Company uses the rate implicit in the lease discount payments
as the incremental borrowing rate to calculate the net present value; however, the rate implicit in the lease is not readily determinable
for their corporate office lease. In this case, the Company estimated its incremental borrowing rate of 5.75% as the interest rate it
could have incurred to borrow an amount equal to the lease payments in a similar economic environment on a collateralized basis over
a term similar to the lease term . The Company estimated its rate based on observable risk-free interest rate and credit spreads for
commercial debt of a similar duration as to what rate would have been effective for the Company.
On
September 8, 2021, the Company entered into an equipment lease agreement for VOIP phone equipment. The lease term is for sixty months,
with a monthly lease payment of approximately $300. The Company assessed the equipment lease as an operating lease. The Company determined
the Right of Use asset and Lease liability values at inception as approximately $17,000 calculated at the present value of all future
lease payments for the lease term, using an incremental borrowing rate of 5.75%.
The
following is a schedule of maturities of lease liabilities as of March 31, 2023:
SCHEDULE OF MATURITIES
OF LEASE LIABILITIES
| |
| | |
2024 | |
$ | 87,808 | |
2025 | |
| 87,808 | |
2026 | |
| 54,709 | |
Total future minimum lease payments | |
| 230,325 | |
Less: imputed interest | |
| 17,332 | |
Total | |
$ | 212,993 | |
NOTE
17 – COMMITMENTS AND CONTINGENCIES
Executive
Employment Agreements –Gerald Easterling
On
April 1, 2015, the Company entered into an employment agreement with Gerald Easterling at the time as the Company’s President,
effective as of April 1, 2015 (the “Employment Agreement”).
The
Employment Agreement is terminable at will and each provide for a base annual salary of $96,000. On May 4, 2021, the Company’s
Board of Directors approved a salary for Mr. Easterling of $180,000 per annum. In addition, the Employment Agreement provides that the
employee is entitled, at the sole and absolute discretion of the Company’s Board of Directors, to receive performance bonuses.
Mr. Easterling will also be entitled to certain benefits including health insurance and monthly allowances for cell phone and automobile
expenses.
The
Employment Agreement provides that in the event the employee is terminated without cause or resigns for good reason (as defined in their
Employment Agreement), the employee will receive, as severance the employee’s base salary for a period of 60 months following the
date of termination. In the event of a change of control of the Company, the employee may elect to terminate the Employment Agreement
within 30 days thereafter and upon such termination would receive a lump sum payment equal to 500% of the employee’s base salary.
The
Employment Agreement contains certain restrictive covenants relating to non-competition, non-solicitation of customers and non-solicitation
of employees for a period of one year following termination of the employee’s Employment Agreement.
Gary
Shover
A
shareholder of NaturalShrimp Holdings, Inc. (“NSH”), Gary Shover, filed suit against the Company on August 11, 2020 in the
Northern District of Texas, Dallas Division, alleging breach of contract for the Company’s failure to exchange common shares of
the Company for shares Mr. Shover owns in NSH. On November 15, 2021, a hearing was held before the US District Court for the Northern
District of Texas, Dallas Division at which time Mr. Shover and the Company presented arguments as to why the Court should approve a
joint motion for settlement. After considering the argument of counsel and taking questions from those NSH Shareholders who were present
through video conferencing link, the Court approved the motion of the parties to allow Mr. Shover and all like and similarly situated
NSH Shareholders to exchange each share of NSH held by a NSH Shareholder for a share of the Company. A final Order was signed on December
6, 2021 and the case was closed by an Order of the Court of the same date. The Company is to issue approximately 93 million shares in
settlement, which as of December 6, 2021 was recognized as stock payable on the Company’s balance sheet, and its fair value of
$29,388,000, based on the market value of the Company’s common shares of $0.316 on the date the case was closed, has been recognized
in the Company’s statement of operations as legal settlement. As of March 31, 2022, 28,494,706 of the shares presented in Stock
Payable have been issued, with the fair value of $9,415,950 reclassified out of Stock Payable. In the year ended March 31, 2023, an additional
61,558,203 of shares of common stock with a fair value of $19,445,284 were issued out of the Stock Payable.
Merger
Agreement
On
October 24, 2022, the Company entered into a Merger Agreement (as it may be amended, supplemented, or otherwise modified from time to
time, the “Merger Agreement”), by and among the Company, Yotta Acquisition Corporation, a Delaware corporation (“Yotta”),
and Yotta Merger Sub, Inc., a Nevada corporation and a wholly owned subsidiary of Yotta (“Merger Sub”). The Merger Agreement
and the transactions contemplated thereby (the “Transactions”) were approved by the board of directors of each of the Company,
Yotta, and Merger Sub.
The
Merger Agreement provides, among other things, that Merger Sub will merge with and into the Company, with the Company as the surviving
company (the “Surviving Company”) in the merger and, after giving effect to such merger, the Company shall be a wholly-owned
subsidiary of Yotta (the “Merger”). In addition, Yotta will be renamed “NaturalShrimp, Incorporated” or such
other name as shall be designated by the Company. Other capitalized terms used, but not defined, herein have the respective meanings
given to such terms in the Merger Agreement.
The
Merger Agreement provides for aggregate consideration to be issued to securityholders of the Company of 17,500,000 shares (the “Closing
Merger Consideration Shares”) of Yotta’s common stock, par value $0.0001 per share (“Yotta Shares”), to be issued
at the effective time of the Merger (the “Effective Time”), plus an additional (i) 5,000,000 Yotta Shares if the Surviving
Corporation has at least $15,000,000 in revenue during the fiscal year ended March 31, 2024 and (ii) 5,000,000 Yotta Shares if the Surviving
Corporation has at least $30,000,000 in revenue during the fiscal year ended March 31, 2025 (collectively, the “Contingent Merger
Consideration Shares”).
In
accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time each share of Common Stock outstanding
or deemed outstanding pursuant to the provisions discussed immediately below as of immediately prior to the Effective Time will be converted
into the right to receive its allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares
(to the extent the required revenue thresholds are met).
Pursuant
to the terms of the Merger Agreement and agreements that, pursuant to the Merger Agreement, the Company will enter into with holders
of such convertible securities, such convertible securities will be canceled prior to the closing of the Merger in exchange (except for
the Series A Convertible Preferred Stock of the Company, par value $0.0001 per share (the “Series A Preferred”) for a cash
payment or Yotta Shares as follows: (i) at the option of the holder thereof, each outstanding warrant to purchase shares of Common Stock
will be canceled in exchange for a cash payment based on the value thereof or treated as exercised for shares of Common Stock, in each
case based on an adjusted exercise price and as otherwise set forth in the Merger Agreement and/or the individual agreements, and if
treated as exercised, converted into the right to receive such deemed shares of Common Stock’s allocable portion of the Closing
Merger Consideration Shares and the Contingent Merger Consideration Shares; (ii) each outstanding share of Series F Convertible Preferred
Stock of the Company, par value $0.0001 per share, will be canceled and treated as if converted into shares of Common Stock at an adjusted
conversion rate as set forth in the Merger Agreement and/or such individual agreements, and converted into the right to receive such
deemed shares of Common Stock’s allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration
Shares; and (iii) each outstanding share of Series E Convertible Preferred Stock of the Company, par value $0.0001 per share (the “Series
E Preferred”), will be canceled and treated as if converted into shares of Common Stock at an adjusted conversion rate as set forth
in the Merger Agreement and/or such individual agreements, and converted into the right to receive such deemed shares of Common Stock’s
allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares. In addition, each holder
of Series E Preferred will be entitled to receive at the Effective Time an additional number of Closing Merger Consideration Shares as
are necessary to ensure that the per-share value of the Yotta Shares that such stockholder is entitled to receive is not less than the
per-share value (based on the effective purchase price) of the aggregate Yotta Shares then held by any Yotta stockholder after taking
into account any newly-issued Yotta Shares that such Yotta stockholder acquires directly from Yotta prior to the closing of the Merger
(the “Closing”) (which will reduce the number of Closing Merger Consideration Shares that will be issued to the Company’s
other securities holders). The Series A Preferred will be cancelled and retired without any conversion thereof and for no consideration.
As
noted in Notes 8, 9 and 12, the Company entered into Restructuring Agreements as required in the Merger Agreement.
The
Business Combination is expected to be accounted for as a reverse merger and recapitalization of NaturalShrimp into Yotta in accordance
with GAAP because NaturalShrimp has been determined to be the accounting acquirer under ASC 805 under the no-redemption and full redemption
scenarios. Under this method of accounting, Yotta will be treated as the “acquired” company for financial reporting purposes.
Accordingly, the combined assets, liabilities and results of operations of NaturalShrimp will become the historical financial statements
of NaturalShrimp Incorporated, and Yotta’s assets, liabilities and results of operations will be consolidated with NaturalShrimp
beginning on the acquisition date. For accounting purposes, the financial statements of NaturalShrimp Incorporated will represent a continuation
of the financial statements of NaturalShrimp with the transaction being treated as the equivalent of NaturalShrimp issuing stock for
the net assets of Yotta, accompanied by a recapitalization. The net assets of Yotta will be stated at historical cost, with no goodwill
or other intangible assets recorded. Operations prior to the Business Combination will be presented as those of NaturalShrimp in future
reports of NaturalShrimp Incorporated.
NOTE
18 – SUBSEQUENT EVENTS
GHS
2022 Purchase Agreement
Subsequent
to the year ended March 31, 2023, the Company sold 40,187,311 shares of common stock at a gross amount of approximately $1,400,000, at
share prices ranging from $0.03 to $0.04.
10,000,000
Common Stock Equity Financing
On
April 28, 2023, the Company entered into an Equity Financing Agreement (“Equity Financing Agreement”) and Registration
Rights Agreement with GHS. Under the terms of the Equity Financing Agreement, GHS agreed to provide the Company with up to $10,000,000
upon effectiveness of a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities
and Exchange Commission (the “Commission”). The Registration Statement has not yet been filed.
Following
effectiveness of the Registration Statement, the Company shall have the discretion to deliver puts to GHS and GHS will be obligated to
purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) based on the investment
amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice shall not
exceed two hundred percent (200%) of the average daily trading dollar volume of the Company’s Common Stock during the ten (10)
trading days preceding the put, so long as such amount does not equal less than ten thousand dollars ($10,000) or greater than one million
dollars ($1,000,000). Pursuant to the Equity Financing Agreement, GHS and its affiliates will not be permitted to purchase and the Company
may not put shares of the Company’s Common Stock to GHS that would result in GHS’s beneficial ownership equaling more than
4.99% of the Company’s outstanding Common Stock. The price of each put share shall be equal to eighty percent (80%) of the Market
Price (as defined in the Equity Financing Agreement). Following an up-list to the NASDAQ or equivalent national exchange, the price of
each put share shall be equal to ninety percent (90%) of the Market Price, subject to a floor price of $1.00 per share. Puts may be delivered
by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the Registration Statement or the date
on which GHS has purchased an aggregate of $10,000,000 worth of Common Stock under the terms of the Equity Financing Agreement.
GHS
Purchase Agreement
On
May 9, 2023, the Company entered into a purchase agreement (the “GHS Purchase Agreement”) with GHS pursuant which the Company
may require GHS to purchase a maximum of up to 45,923,929 shares of the Company’s common stock (“GHS Purchase Shares”)
based on a total aggregate purchase price of up to $6,000,000 over a one-year term that ends on May 9, 2024. The Company intends to use
the net proceeds from this offering for working capital and general corporate purposes.
The
GHS Purchase Agreement provides that, upon the terms and subject to the conditions and limitations set forth in the agreement, the Company
has the right from time to time during the term of the agreement, in its sole discretion, to deliver to GHS a purchase notice (a “Purchase
Notice”) directing GHS to purchase (each, a “GHS Purchase”) a specified number of GHS Purchase Shares. A GHS Purchase
will be made in a minimum amount of $10,000 and up to a maximum of $1,500,000 and provided that, the purchase amount for any purchase
will not exceed 200% of the average of the daily trading dollar volume of the Company’s common stock during the 10 business days
preceding the purchase date. Notwithstanding the foregoing dollar limitations, the Company and GHS may, from time to time, mutually agree
(in writing) to waive the aforementioned limitations for a relevant Purchase Notice, which waiver, for the avoidance of doubt, shall
not exceed the 4.99% beneficial ownership limitation contained in the GHS Purchase Agreement. The “Purchase Price” means,
with respect to a purchase made pursuant to the GHS Purchase Agreement, 90% of the lowest VWAP (as defined in the GHS Purchase Agreement)
during the Valuation Period (the ten (10) consecutive business days immediately preceding, but not including, the applicable purchase
date). The Company shall deliver a number of GHS Purchase Shares equal to 112.5% of the aggregate purchase amount for such GHS Purchase
divided by the Purchase Price per share for such GHS Purchase, against payment by GHS to the Company of the purchase amount with respect
to such Purchase (less documented deposit and clearing fees, if any), as full payment for such GHS Purchase Shares via wire transfer
of immediately available funds.
If
there are any default events, as set forth in the GHS Purchase Agreement, has occurred and is continuing, the Company shall not deliver
to GHS any Purchase Notice.
Further,
pursuant to the terms of the GHS Purchase Agreement, from May 9, 2023 until the date that is the later of (i) the closing of the transactions
whereby Yotta Merger Sub, Inc. will merge with and into the Company, with the Company as the surviving company (the “Merger”);
and (ii) the 12 month anniversary of the initial closing pursuant to the Section 2(a) of GHS Purchase Agreement, upon any issuance by
the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination
of units thereof (a “Subsequent Financing”), GHS shall have the right to participate in any financing, up to an amount of
the Subsequent Financing equal to 100% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions
and price provided for in the Subsequent Financing. Following the Merger, the Participation Maximum shall be 50% of the Subsequent Financing.
Series
E Preferred Stock
On
May 1, 2023, one of the holders converted 600 Series E Preferred Stock into 23,989,570 shares of common stock. The conversion represented
their remaining Series E Preferred Stock, including the 10% increase and accrued dividends in kind.
April
2023 Promissory Note
On
April 21, 2023, the Company entered into a $60,000 promissory note with Yotta Investment LLC, with no interest to accrue on the principal
balance. The promissory note is to be settled on the date of closing of the business combination contemplated by the Merger Agreement
with Yotta.
May
2023 Promissory Note
On
May 17, 2023, the Company entered into an additional $60,000 promissory note with Yotta Investment LLC, with no interest to accrue
on the principal balance. The promissory note is to be settled on the date of closing of the business combination contemplated by
the Merger Agreement with Yotta.